{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:25:47Z","timestamp":1792301147938,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013425","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000}}],"reference-count":804,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013425.pub2","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T06:40:31Z","timestamp":1719988831000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders"],"prefix":"10.1002","volume":"2024","author":[{"given":"Khasan","family":"Ibragimov","sequence":"additional","affiliation":[{"name":"Ecole des Hautes Etudes en Sante Publique (EHESP); Hautes Etudes en Sante Publique (EHESP); Paris France"},{"name":"Epicentre; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Peter","family":"Keane","sequence":"additional","affiliation":[{"name":"Operational Centre Paris; M\u00e9decins Sans Fronti\u00e8res; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Carre\u00f1o Glar\u00eda","sequence":"additional","affiliation":[{"name":"Operational Centre Barcelona; M\u00e9decins Sans Fronti\u00e8res; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cheng","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University School of Medicine; Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto Eduardo","family":"Llosa","sequence":"additional","affiliation":[{"name":"Epicentre; Paris France"},{"name":"Operational Centre Barcelona; M\u00e9decins Sans Fronti\u00e8res; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"10.1002\/14651858.CD013425.pub2-BIB0001|cit1","unstructured":"Altamura AC HGBQ - Olanzapine verus haloperidol in partial responder schizophrenic patients Supplied by Eli Lilly 2000"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013425.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"S297","DOI":"10.1016\/S0924-977X(99)80373-3","article-title":"Olanzapine in the treatment of paranoid schizophrenia","volume":"9","author":"Altamura","year":"1999","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/136515002753724117","article-title":"Is olanzapine better than haloperidol in resistant schizophrenia? A double-blind study in partial responders","volume":"6","author":"Altamura","year":"2002","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0004|cit4","first-page":"257","article-title":"Olanzapine in the treatment of schizophrenia: an open label comparative trial from North India","volume":"43","author":"Avasthi","year":"2001","journal-title":"Indian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0278-5846(01)00322-0","article-title":"Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients","volume":"26","author":"Barak","year":"2002","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0006|cit6","unstructured":"Baker R W Julier B Stauffer V Manic-like symptoms in schizophrenic patients treated with olanzapine, haloperidol and placebo 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany 2001"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1192\/bjp.174.1.23","article-title":"A randomized, double-blind comparison of the incidence of tardive dyskinesia during long-term treatment with olanzapine or haloperidol","volume":"174","author":"Dellva","year":"1999","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0924-977X(96)00392-6","article-title":"Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial","volume":"7","author":"Hamilton","year":"1997","journal-title":"European Neuropsychopharmacology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD013425.pub2-BIB0009|cit9","first-page":"13","article-title":"Safety of olanzapine","volume":"58","author":"Tollefson","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0920-9964(97)88362-4","article-title":"The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia","volume":"29","author":"Beasley","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1176\/ps.48.12.1571","article-title":"Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia","volume":"48","author":"Dellva","year":"1997","journal-title":"Psychiatric Services"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Edgell ET Hamilton SH Revicki DA Genduso LA Tollefson GD Costs of olanzapine treatment compared with haloperidol for schizophrenia: results from a randomized clinical trial Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum; 1998 July 12-16; Glasgow, Scotland, UK 1998","DOI":"10.1016\/S0924-977X(98)80406-9"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0013|cit13","unstructured":"Nemeroff CB Quality of life and new antipsychotics Xth World Congress of Psychiatry; August 23-28; Madrid, Spain 1996"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Revicki D Genduso L Olanzapine versus haloperidol therapy for chronic schizophrenia: impact on deficit syndrome 8th European College of Neuropsychopharmacology Congress; Sep 30-Oct 4; Venice; Italy 1995","DOI":"10.1016\/0924-977X(95)90586-3"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0015|cit15","first-page":"522","article-title":"Long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol","volume":"32","author":"Street","year":"1996","journal-title":"Psychopharmacology Bulletin"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0920-9964(97)88754-3","article-title":"What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine?","volume":"29","author":"Tamura","year":"1998","journal-title":"Schizophrenia Research"},{"issue":"9","key":"10.1002\/14651858.CD013425.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1176\/ajp.154.9.1248","article-title":"Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol","volume":"154","author":"Tollefson","year":"1997","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Tran P Beasley C Tollefson G Crawford A Dellva M Gusman S Acute and long-term results of the dose ranging double-blind olanzapine trial XXth Collegium Internationale Neuro-psychopharmacologicum; June 23-27; Melbourne, Australia 1996","DOI":"10.1016\/0924-977X(96)87573-0"},{"issue":"1,2","key":"10.1002\/14651858.CD013425.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0920-9964(95)95525-E","article-title":"Olanzapine: a promising atypical antipsychotic agent","volume":"15","author":"Tran","year":"1995","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4088\/JCP.v58n0505","article-title":"Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia","volume":"58","author":"Tran","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1192\/bjp.172.6.499","article-title":"Oral olanzapine versus oral haloperidol in the maintenance tratement of schizophrenia and related psychoses","volume":"172","author":"Tran","year":"1998","journal-title":"British Journal of Psychiatry"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0920-9964(97)88829-9","article-title":"A blinded, controlled, long-term study of the comparative incidence of treatment-resistant tardive dyskinesia with olanzapine or haloperidol","volume":"29","author":"Wright","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0023|cit23","unstructured":"Baker R W Julier B Stauffer V Manic-like symptoms in schizophrenic patients treated with olanzapine, haloperidol and placebo 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany 2001"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0024|cit24","first-page":"89","article-title":"Obsessive-compulsive symptoms in schizophrenia - a comparison of olanzapine and placebo","volume":"32","author":"Baker","year":"1996","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial","volume":"14","author":"Tollefson","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD013425.pub2-BIB0026|cit26","first-page":"13","article-title":"Safety of olanzapine","volume":"58","author":"Tollefson","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0920-9964(97)88362-4","article-title":"The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia","volume":"29","author":"Beasley","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0028|cit28","unstructured":"Beasley CM Tollefson GD Beuzen JN Dellva MA Sanger TM Paul S Acute and long-term results of the North American double-blind olanzapine trial Schizophrenia - Breaking down the Barriers, 4th International Conference; October 6-9; Vancouver; BC, Canada 1996"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0029|cit29","unstructured":"Crawford AM Beasley CM Tollefson GD Olanzapine - impact of an atypical antipsychotic candidate on prolactin release American Psychiatric Association, 149th Annual Meeting; May 4-9 1996"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0030|cit30","unstructured":"Crawford AM Beasley CM Tollefson GD The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration 10th European College of Neuropsychopharmacology Congress; Sep 13-17; Vienna, Austria 1997"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0031|cit31","first-page":"P2016","article-title":"The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations","volume":"9","author":"Crawford","year":"1997","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1176\/ps.48.12.1571","article-title":"Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia","volume":"48","author":"Dellva","year":"1997","journal-title":"Psychiatric Services"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0033|cit33","doi-asserted-by":"crossref","unstructured":"Edgell ET Hamilton SH Revicki DA Genduso LA Tollefson GD Costs of olanzapine treatment compared with haloperidol for schizophrenia: results from a randomized clinical trial Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum; July 12-16; Glasgow, Scotland, UK 1998","DOI":"10.1016\/S0924-977X(98)80406-9"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0893-133X(97)00111-5","article-title":"Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial","volume":"18","author":"Hamilton","year":"1998","journal-title":"Neuropsychopharmacology"},{"issue":"2,3","key":"10.1002\/14651858.CD013425.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/0920-9964(96)85438-7","article-title":"Quality of life outcomes of olanzapine, a new atypical antipsychotic agent","volume":"18","author":"Martin","year":"1996","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00004714-200102000-00004","article-title":"Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial","volume":"21","author":"Perry","year":"2001","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0037|cit37","doi-asserted-by":"crossref","unstructured":"Revicki D Genduso L Effect of olanzapine on deficit syndrome symptoms in chronic schizophrenia 8th European College of Neuropsychopharmacology Congress; Sep 30 - Oct 4; Venice; Italy 1995","DOI":"10.1016\/0924-977X(95)90587-4"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0038|cit38","doi-asserted-by":"crossref","unstructured":"Sanger T Tollefson GD Lieberman JA Tohen M Olanzapine versus haloperidol in the treatment of first-episode psychosis American Psychiatric Association. 150th Annual Meeting; San Diego; CA, USA 1997","DOI":"10.1016\/S0920-9964(97)82552-2"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0039|cit39","unstructured":"Sanger T Tollefson GD A controlled study on the course of primary and secondary negative symptoms American Psychiatric Association, 150th Annual Meeting; San Diego; CA, USA 1997"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0040|cit40","first-page":"638","article-title":"Preclinical and clinical observations of olanzapine (a new antipsychotic)","volume":"30","author":"Satterlee","year":"1994","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Street J Dellva M Tamura R Sanger T Tollefson G A comparison of extrapyramidal syndromes between olanzapine and placebo in schizophrenia 9th Congress of the European College of Neuropsychopharmacology, Amsterdam, The Netherlands 1996","DOI":"10.1016\/0924-977X(96)88096-5"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0042|cit42","doi-asserted-by":"crossref","unstructured":"Street JS Dellva MA Tamura RN Sanger T Tollefson GD Comparison of extrapyramidal syndromes between olanzapine and placebo in schizophrenia American Psychiatric Association, 149th Annual Meeting; May 4-9 1996","DOI":"10.1016\/0924-977X(96)82951-8"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0043|cit43","doi-asserted-by":"crossref","unstructured":"Street JS Dellva MA Tamura RN Sanger T Tollefson GD Comparison of extrapyramidal syndromes between olanzapine and placebo in schizophrenia XXth Collegium Internationale Neuro-psychopharmacologicum; June 23-27; Melbourne; Australia 1996","DOI":"10.1016\/0924-977X(96)88096-5"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Street JS Dellva MA Tamura RN Sanger T Tollefson GD Comparison of extrapyramidal syndromes between olanzapine and placebo in schizophrenia Xth World Congress of Psychiatry; August 23-28; Madrid; Spain 1996","DOI":"10.1016\/0924-977X(96)88096-5"},{"issue":"9","key":"10.1002\/14651858.CD013425.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1176\/ajp.154.9.1248","article-title":"Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol","volume":"154","author":"Tollefson","year":"1997","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0046|cit46","unstructured":"Tollefson GD Beasley CM Tran PV Sanger T Olanzapine: an exciting atypical antipsychotic the clinical experience 8th European College of Neuropsychopharmacology Congress; Sep 30-Oct 4; Venice; Italy 1995"},{"issue":"11","key":"10.1002\/14651858.CD013425.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0006-3223(98)00093-6","article-title":"A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.","volume":"43","author":"Tollefson","year":"1998","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0048|cit48","unstructured":"Tollefson GD Sanger TM Beasley CM The course of primary and secondary negative symptoms in a controlled trial with Olanzapine XXth Collegium Internationale Neuro-psychopharmacologicum; June 23-27; Melbourne; Australia 1996"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0049|cit49","doi-asserted-by":"crossref","unstructured":"Tollefson GD Sanger TM Beasley CM The course of primary and secondary negative symptoms in a controlled trial with olanzapine American Psychiatric Association, 149th Annual Meeting; May 4-9 1996","DOI":"10.1016\/0924-977X(96)83219-6"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0050|cit50","first-page":"192","article-title":"The course of primary and secondary negative symptoms in a controlled trial with olanzapine","volume":"24","author":"Tollefson","year":"1997","journal-title":"Schizophrenia Research (Special Issue - The VIth International Congress on Schizophrenia Research; April 12-16; Colorado Springs; CO, USA)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Tollefson GD Sanger TM Beasley CM The course of primary and secondary negative symptoms in a placebo- and comparator-controlled trial of the atypical antipsychotic olanzapine 9th European College of Neuropsychopharmacology Congress; Sep 21-25; Amsterdam; The Netherlands 1996","DOI":"10.1016\/0924-977X(96)83219-6"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.154.4.466","article-title":"Negative symptoms: a path analytic approach to a double-blind, placebo and haloperidol controlled clinical trial with olanzapine","volume":"154","author":"Tollefson","year":"1997","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0053|cit53","unstructured":"Tollefson GD The value of atypical antipsychotic medications American Psychiatric Association, 150th Annual Meeting; San Diego; CA, USA 1997"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0054|cit54","doi-asserted-by":"crossref","unstructured":"Tollefson GD Update on new atypical antipsychotics 8th European College of Neuropsychopharmacology Congress; Sep 30-Oct 4; Venice; Italy 1995","DOI":"10.1016\/0924-977X(95)90151-3"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0055|cit55","doi-asserted-by":"crossref","unstructured":"Tran P Beasley C Tollefson G Beuzen J Dellva M Sanger T Acute and long-term results of the North American double-blind olanzapine trial 8th European College of Neuropsychopharmacology Congress. Sep 30-Oct 4, Venice, Italy 1995","DOI":"10.1016\/0924-977X(95)90588-5"},{"issue":"Suppl","key":"10.1002\/14651858.CD013425.pub2-BIB0056|cit56","first-page":"267S","article-title":"Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent","volume":"10","author":"Tran","year":"1994","journal-title":"Neuropsychopharmacology"},{"issue":"1,2","key":"10.1002\/14651858.CD013425.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0920-9964(95)95525-E","article-title":"Olanzapine: a promising atypical antipsychotic agent","volume":"15","author":"Tran","year":"1995","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1192\/bjp.172.6.499","article-title":"Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses","volume":"172","author":"Tran","year":"1998","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0059|cit59","first-page":"A47","article-title":"Additional clinical experience with olanzapine, an atyical antipsychotic","volume":"9","author":"Williamson","year":"1995","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0060|cit60","first-page":"A47","article-title":"Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent","volume":"9","author":"Williamson","year":"1995","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0925-4927(01)00085-3","article-title":"Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint","volume":"107","author":"Bernardo","year":"2001","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0062|cit62","unstructured":"Boulay L Contrasting the effects of haloperidol and olanzapine on attention and working memory in schizophrenia: a double-blind flexible dose study National Library of Canada 2003"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1080\/13546800601069534","article-title":"Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: olanzapine versus haloperidol","volume":"12","author":"Boulay","year":"2007","journal-title":"Cognitive Neuropsychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1176\/appi.ajp.162.1.124","article-title":"Olanzapine treatment of residual positive and negative symptoms","volume":"162","author":"Buchanan","year":"2005","journal-title":"Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0920-9964(03)80437-1","article-title":"Olanzapine treatment of residual positive and negative symptoms","volume":"60","author":"Buchanan","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/0269881108093883","article-title":"Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study","volume":"23","author":"Kelly","year":"2009","journal-title":"Journal of Psychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD013425.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1176\/appi.ajp.162.7.1392","article-title":"Olanzapine and haloperidol for residual symptoms","volume":"162","author":"Haan","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"S309","DOI":"10.1016\/S0924-977X(03)92022-0","article-title":"Quality of life and clinical outcomes for Asian outpatients with schizophrenia: a double-blind randomised comparison of olanzapine and haloperidol","volume":"13","author":"Chaudhry","year":"2003","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0069|cit69","first-page":"1157","article-title":"Asian outpatients with schizophrenia: a double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol","volume":"89(8)","author":"Chaudhry","year":"2006","journal-title":"Journal of the Medical Association of Thailand"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00213-013-2994-z","article-title":"Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone","volume":"227","author":"Ayesa-Arriola","year":"2013","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.psychres.2006.08.005","article-title":"Interleukin-12 plasma levels in drug-naive patients with a first episode of psychosis: effects of antipsychotic drugs","volume":"158","author":"Crespo-Facorro","year":"2008","journal-title":"Psychiatry Research"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ebmh.10.3.74","article-title":"Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis but have differing side effects","volume":"10","author":"Crespo-Facorro","year":"2007","journal-title":"Evidence-Based Mental Health"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jpsychires.2010.11.002","article-title":"Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine","volume":"45","author":"Crespo-Facorro","year":"2011","journal-title":"Journal of Psychiatric Research"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00213-011-2392-3","article-title":"Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis","volume":"219","author":"Crespo-Facorro","year":"2012","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1177\/0269881110388332","article-title":"Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison","volume":"25","author":"Crespo-Facorro","year":"2011","journal-title":"Journal of Psychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD013425.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4088\/JCP.v67n1004","article-title":"A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis","volume":"67","author":"Crespo-Facorro","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"717","DOI":"10.4088\/JCP.08m04634","article-title":"Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison","volume":"70(5)","author":"Crespo-Facorro","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD013425.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/j.pnpbp.2008.09.020","article-title":"Effect of antipsychotic drugs on brain morphometry: a randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine","volume":"32","author":"Crespo-Facorro","year":"2008","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"1-3","key":"10.1002\/14651858.CD013425.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.schres.2011.06.006","article-title":"Using structural equations to test for a direct effect of some antipsychotics on triglyceride levels in drug-na\u00efve first-episode psychosis patients","volume":"131","author":"Diaz","year":"2011","journal-title":"Schizophrenia Research"},{"issue":"1-3","key":"10.1002\/14651858.CD013425.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.schres.2010.06.002","article-title":"Possible effects of some antipsychotic drugs on C-reactive protein in a drug-na\u00efve psychotic sample","volume":"121","author":"Diaz","year":"2010","journal-title":"Schizophrenia Research"},{"issue":"2-3","key":"10.1002\/14651858.CD013425.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.psychres.2012.10.011","article-title":"Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables","volume":"206","author":"D\u00edaz","year":"2013","journal-title":"Psychiatry Research"},{"issue":"8","key":"10.1002\/14651858.CD013425.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/ajmg.b.30405","article-title":"Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment","volume":"141","author":"Mata","year":"2006","journal-title":"American Journal of Medical Genetics Part B: Neuropsychiatric Genetics"},{"issue":"1-3","key":"10.1002\/14651858.CD013425.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.schres.2008.02.011","article-title":"Lack of influence of COMT Val158Met genotype on cognition in first-episode non-affective psychosis","volume":"102","author":"Mata","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1017\/S0033291713000330","article-title":"Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis","volume":"44","author":"Pelayo-Teran","year":"2014","journal-title":"Psychological Medicine"},{"issue":"117","key":"10.1002\/14651858.CD013425.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.schres.2010.02.219","article-title":"Early response to antipsychotics as a marker of treatment response of psychosis","volume":"2","author":"Pelayo-Teran","year":"2010","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0086|cit86","first-page":"S551","article-title":"Catechol-o-methyltransferase val158met in first episode psychosis: prognostic factor or negative trait marker?","volume":"unknown","author":"Pelayo-Teran","journal-title":"Psychotic Disorders and Antipsychotics - Antipsychotics (clinical)"},{"issue":"11","key":"10.1002\/14651858.CD013425.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.4088\/JCP.v68n1113","article-title":"A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone","volume":"68","author":"Perez-Iglesias","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1-3","key":"10.1002\/14651858.CD013425.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.schres.2007.10.022","article-title":"Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population","volume":"99","author":"Perez-Iglesias","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0089|cit89","first-page":"505","article-title":"One year randomized clinical trial of haloperidol, olanzapine or risperidone to determine weight gain pattern in a drug-naive population of first episode psychotic patients","volume":"33","author":"Perez-Iglesias","journal-title":"Schizophrenia Bulletin"},{"issue":"2-3","key":"10.1002\/14651858.CD013425.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.schres.2008.09.028","article-title":"Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naive population","volume":"107","author":"Perez-Iglesias","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/JCP.0b013e318172b8e6","article-title":"Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment","volume":"28","author":"Perez-Iglesias","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0092|cit92","first-page":"00","article-title":"Predictors of antipsychotic-induced weight gain after the first 3 years of treatment","volume":"4","author":"P\u00e9rez-Iglesias","year":"2010","journal-title":"Early Intervention in Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1017\/S1461145713001053","article-title":"Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors","volume":"17","author":"P\u00e9rez-Iglesias","year":"2014","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/JCP.0b013e318272688b","article-title":"Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis","volume":"32","author":"P\u00e9rez-Iglesias","year":"2012","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.schres.2012.07.014","article-title":"Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine","volume":"141","author":"Roiz-Santi\u00e1\u00f1ez","year":"2012","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0096|cit96","first-page":"574","article-title":"Comparison between the effect of typical and atypical antipsychotics on cognition: a three-month follow up in first episodes of psychosis","volume":"33","author":"Sanchez-Cubillo","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0097|cit97","first-page":"175","article-title":"\u6c1f\u54cc\u5576\u9187\u4e0e\u5965\u6c2e\u5e73\u6cbb\u7597\u7cbe\u795e\u5206\u88c2\u75c7\u7597\u6548\u63a2\u8ba8","volume":"28","year":"2016","journal-title":"\u6d77\u5ce1\u836f\u5b66"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/appi.ajp.160.2.303","article-title":"Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study","volume":"160","author":"Haan","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0099|cit99","first-page":"179","article-title":"Subjective experience and d2 receptor occupancy in patients with schizophrenia, treated with low dose olanzapine or haloperidol; a randomized double-blind study","volume":"3 Suppl 1","author":"Haan","year":"2002","journal-title":"Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0100|cit100","first-page":"31","article-title":"Comparative efficacy of haloperidol and olanzapine in patients of schizophrenia: a 6 month follow up trial","volume":"15","author":"Dhar","year":"2010","journal-title":"JMHHB"},{"issue":"01","key":"10.1002\/14651858.CD013425.pub2-BIB0101|cit101","first-page":"23","article-title":"Controlled study in refractory schizophrenia treatment olanzapine and haloperidol [Google Translate]","volume":"21","year":"2013","journal-title":"China Journal of Health Psychology [\u4e2d\u56fd\u5065\u5eb7\u5fc3\u7406\u5b66\u6742\u5fd7]"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0102|cit102","first-page":"S370","article-title":"The \"Neuroleptic Strategy Study\" (NeSSy)-first vs. second generation antipsychotics for the treatment of schizophrenia","volume":"39","author":"Gruender","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0103|cit103","first-page":"S233","article-title":"Antipsychotic Serum Concentrations in the \"Neuroleptic Strategy Study\"(NeSSy)","volume":"41","author":"Gruender","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD013425.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S2215-0366(16)00085-7","article-title":"Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study","volume":"3","author":"Gr\u00fcnder","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1177\/1740774516639910","article-title":"Patient-oriented randomisation: a new trial design applied in the Neuroleptic Strategy Study","volume":"13","author":"Schulz","year":"2016","journal-title":"Clinical Trials"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1177\/1740774516639910","article-title":"Disparate effects of first and second generation antipsychotics on cognition in schizophrenia\u2013findings from the randomized NeSSy trial","volume":"29","author":"Veselinovi\u0107","year":"2019","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0107|cit107","unstructured":"Tran PV Beasley CM Tollefson GD Creanga D Zhang F Wang J Clinical experience with olanzapine in patients of African, Asian, and Hispanic descent Meeting of the American Psychiatric Association. Washington, DC, USA 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0108|cit108","unstructured":"Tran PV Beasley CM Tollefson GD Creanga D Zhang F Wang J Clinical experience with olanzapine in patients of African, Asian, and Hispanic descent World Psychiatric Association; Hamburg, Germany 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0109|cit109","unstructured":"Tran PV Cousins LM Creanga D Tollefson GD Vangala S Wang J Clinical experience with olanzapine in patients of African, Asian, and Hispanic descent ACNP. Hawaii, USA 1998"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0110|cit110","unstructured":"Tran PV Creanga D Zhang F Wang J Vangala S Cousins L Clinical experience with olanzapine in ethnic subgroups NCDEU. Boca Raton, FL, USA 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0111|cit111","unstructured":"Tran PV Zhang F Hwu HG Liehmak F Efficacy and safety study comparing olanzapine versus haloperidol in the treatment of Chinese patients with schizophrenia in Taiwan and Hong Kong APA Annual Meeting, May 15-20, Washington, DC 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0112|cit112","unstructured":"Vangala S Zhang F Tran P Sze S Efficacy and safety study comparing olanzapine versus haloperidol in the treatment of Chinese patients with schizophrenia in Hong Kong Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum; July 12-16; Glasgow, Scotland, UK 1998"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0113|cit113","unstructured":"Zhang F Tran PV Taylor C Hwu GH Chen YS Chang WH Efficacy and safety study comparing olanzapine versus haloperidol in the treatment of Chinese patients with schizophrenia in Taiwan and Hong Kong World Psychiatric Association; Hamburg, Germany 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0114|cit114","unstructured":"Tran PV Creanga D Zhang F Wang J Vangala S Cousins L Clinical experience with olanzapine in ethnic subgroups NCDEU. Boca Raton, FL, USA 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0115|cit115","unstructured":"Tran PV Zhang F Hwu HG Liehmak F Efficacy and safety study comparing olanzapine versus haloperidol in the treatment of Chinese patients with schizophrenia in Taiwan and Hong Kong American Psychiatric Association Annual Meeting; 1999 May 15-20; Washington DC; USA 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0116|cit116","unstructured":"Zhang F Tran PV Taylor C Hwu GH Chen YS Chang WH Efficacy and safety study comparing olanzapine versus haloperidol in the treatment of Chinese patients with schizophrenia in Taiwan and Hong Kong World Psychiatric Association. Hamburg, Germany 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0117|cit117","unstructured":"Data on file Data supplied to the Cochrane Schizophrenia Group 1999"},{"issue":"17","key":"10.1002\/14651858.CD013425.pub2-BIB0118|cit118","first-page":"90","article-title":"\u6c1f\u54cc\u5576\u9187\u4e0e\u5965\u6c2e\u5e73\u6cbb\u7597\u7cbe\u795e\u5206\u88c2\u75c7\u7597\u6548\u548c\u5b89\u5168\u6027","volume":"-","year":"2014","journal-title":"\u4e2d\u56fd\u536b\u751f\u6807\u51c6\u7ba1\u7406"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0119|cit119","first-page":"39","article-title":"Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haoperidol","volume":"18","author":"Inada","year":"2003","journal-title":"International Clinical Psychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013425.pub2-BIB0120|cit120","first-page":"S147","article-title":"Favorable eps profiles of olanzapine measured by the diepss: predictive validity of this scale to differentiate the eps profiles of atypical antipsychotic drugs from conventional antipsychotic drugs in the clinical trial","volume":"3","author":"Inada","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2-3","key":"10.1002\/14651858.CD013425.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0920-9964(01)00314-0","article-title":"Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol","volume":"57","author":"Inada","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1440-1819.2001.00882.x","article-title":"Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multi-center double-blind olanzapine trial","volume":"55","author":"Ishigooka","year":"2001","journal-title":"Psychiatry and Clinical Neurosciences"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0123|cit123","first-page":"43","article-title":"Olanzapine and haloperidol in the treatment of schizophrenia comparative study of excited agitation [Google Translate]","volume":"22","year":"2009","journal-title":"Sichuan Mental Health [\u56db\u5ddd\u7cbe\u795e\u536b\u751f]"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0124|cit124","first-page":"132","article-title":"Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone or haloperidol","volume":"29","author":"Canadian Cognition and Outcome Study Group","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0125|cit125","unstructured":"David SR Purdon S Jones BD Stip E Labelle A Breier AF Olanzapine versus risperidone versus haloperidol in early illness schizophrenia. Education improves outcomes in MDD 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington, USA 1999 97055970"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0920-9964(97)88683-5","article-title":"Olanzapine versus risperidone and haloperidol in the treatment of schizophrenia","volume":"29","author":"Jones","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0127|cit127","doi-asserted-by":"crossref","unstructured":"Jones B Olanzapine versus risperidone and haloperidol in the treatment of schizophrenia 151st Annual Meeting of American Psychiatric Association; May 30-June 4; Toronto; ON, Canada 1998","DOI":"10.1016\/S0920-9964(97)88683-5"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0128|cit128","first-page":"S152","article-title":"Treatment of cognitive deficits with antipsychotic drugs","volume":"4S","author":"Jones","year":"1998","journal-title":"Neurobiology of Aging (Abstracts of 6th International Conference on Alzheimer's Disease and Related Disorders; 1998 Jul 18-23; Amsterdam, the Netherlands)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0129|cit129","unstructured":"Purdon SE Jones B Labelle A Addington D Tollefson G A multicentre comparison of olanzapine, risperidone, and haloperidol on working memory, new learning, and delayed recall of verbal and nonverbal materials in early-phase schizophrenia over a 12-month prospective double-blind clinical trial Schizophrenia Research (Abstracts of The 7th International Congress on Schizophrenia Research; 1999 Apr 17-21; Santa Fe, USA) 1999 150 20137242"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archpsyc.57.3.249","article-title":"Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.","volume":"57","author":"Purdon","year":"2000","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0131|cit131","unstructured":"Purdon SE Jones BDW Stip E Labelle A Addington D Breier A et al and the Canadian Collaborative Group for Research on Cognition in Schizophrenia Olanzapine versus haloperidol versus risperidone in early illness schizophrenia Unpublished typescript 2001"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0132|cit132","unstructured":"Purdon SE Jones BDW Stip E Labelle A Addington Dm Breier A Tollefson GD Olanzapine versus haloperidol versus risperidone in early illness schizophrenia Unpublished data on file 2001 21122407"},{"issue":"3-4","key":"10.1002\/14651858.CD013425.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s00213-003-1505-z","article-title":"Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol","volume":"169","author":"Purdon","year":"2003","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/archpsyc.59.6.571","article-title":"Atypical antipsychotics and cognition in schizophrenia","volume":"59","author":"Sharma","year":"2002","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0135|cit135","first-page":"125","article-title":"Procedural learning over six months double blind treatment with haloperidol, risperidone or olanzapine","volume":"1-2 Suppl","author":"Woodward","year":"2001","journal-title":"Schizophrenia Research (8th International Congress on Schizophrenia Research; 2001 Apr 28 - May 2; British Columbia, Canada)"},{"issue":"2-3","key":"10.1002\/14651858.CD013425.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.schres.2009.09.019","article-title":"Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST)","volume":"115","author":"Boter","year":"2009","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)","volume":"166","author":"Davidson","year":"2009","journal-title":"American Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD013425.pub2-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.schres.2005.06.004","article-title":"The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial","volume":"78","author":"Fleischhacker","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"9618","key":"10.1002\/14651858.CD013425.pub2-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/JCP.0b013e3182199bcc","article-title":"Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial","volume":"31","author":"Malik","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD013425.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"955","DOI":"10.4088\/JCP.10m06529","article-title":"Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST)","volume":"72","author":"Volavka","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajem.2004.02.021","article-title":"Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia","volume":"22","author":"Kinon","year":"2004","journal-title":"American Journal of Emergency Medicine"},{"issue":"1-3","key":"10.1002\/14651858.CD013425.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.schres.2009.02.006","article-title":"Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol","volume":"110","author":"Krakowski","year":"2009","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1097\/01.yic.0000405864.74645.87","article-title":"A prospective longitudinal study of cholesterol and aggression in patients randomized to clozapine, olanzapine and haloperidol","volume":"26","author":"Krakowski","year":"2011","journal-title":"International Clinical Psychopharmacology"},{"issue":"1-3","key":"10.1002\/14651858.CD013425.pub2-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.schres.2011.04.005","article-title":"Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol","volume":"130","author":"Krakowski","year":"2011","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1001\/archpsyc.63.6.622","article-title":"Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Krakowski","year":"2006","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/JCP.0b013e3181d47b5e","article-title":"A prospective longitudinal study of cholesterol and aggression in patients randomized to clozapine, olanzapine, and haloperidol.","volume":"30","author":"Krakowski","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0148|cit148","unstructured":"Krakowski MI Czobor P Clozapine and olanzapine in violent schizophrenics CRISP database (https:\/\/www-commons. cit. nih. gov\/crisp\/index. html)"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/schbul\/sbt117","article-title":"Depression and impulsivity as pathways to violence: implications for antiaggressive treatment.","volume":"40","author":"Krakowski","year":"2013","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4088\/JCP.11m07238","article-title":"Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial","volume":"73","author":"Krakowski","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0151|cit151","first-page":"311","article-title":"Neurocognitive impairment limits the response to treatment of aggression with antipsychotic agents","volume":"37","author":"Krakowski","year":"2011","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3389\/fpsyt.2012.00105","article-title":"Antipsychotic drugs alter functional connectivity between the medial frontal cortex, hippocampus, and nucleus accumbens as measured by H215O PET","volume":"3","author":"Bolding","year":"2012","journal-title":"Frontiers in Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0153|cit153","first-page":"474","article-title":"Limbic rcbf patterns predict treatment response in schizophrenia","volume":"33","author":"Lahti","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"13","key":"10.1002\/14651858.CD013425.pub2-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1038\/npp.2009.94","article-title":"Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia","volume":"34","author":"Lahti","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0155|cit155","first-page":"275","article-title":"A controlled study of olanzapine and haloperidol in the treatment of the acute phase of schizophrenia","volume":"17","author":"Li","year":"2005","journal-title":"Shanghai Archives of Psychiatry [\u4e0a\u6d77\u7cbe\u795e\u533b\u5b66] [\u4e0a\u6d77\u7cbe\u795e\u91ab\u5b78]"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0920-9964(03)80434-6","article-title":"A one-year double-blind comparison of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in patients with schizophrenia","volume":"60","author":"Breier","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0157|cit157","unstructured":"Breier AF Zipursky RB Perkins DO Addington JM Tohen MF David SR A trial of olanzapine versus pbo in the prodrome: protocol and baseline sample 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA 2002"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0920-9964(03)80442-5","article-title":"Drug attitudes and treatment adherence in a clinical trial comparing haloperidol and olanzapine in first episode schizophrenia","volume":"60","author":"Centorrino","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0159|cit159","first-page":"230","article-title":"Comorbid substance use disorder and first episode schizophrenia: acute effects of olanzapine versus haloperidol","volume":"1-2 Suppl","author":"Green","year":"2001","journal-title":"Schizophrenia Research (8th International Congress on Schizophrenia Research; 2001 Apr 28 - May 2; British Columbia, Canada)"},{"issue":"2-3","key":"10.1002\/14651858.CD013425.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.schres.2003.08.001","article-title":"First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol","volume":"66","author":"Green","year":"2004","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0161|cit161","first-page":"S336","article-title":"Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia","volume":"13","author":"Kahn","year":"2003","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0162|cit162","first-page":"196","article-title":"Source monitoring improvement in patients with schizophrenia","volume":"3 Suppl 1","author":"Keefe","year":"2002","journal-title":"Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0163|cit163","doi-asserted-by":"crossref","unstructured":"Keefe R Seidman LJ Christensen B Hamer RM Yurgelun-Todd D Lewine R Neurocognitive effects of olanzapine and low-dose haloperidol: a two-year treatment study in first episode psychosis Schizophrenia Research 2003 289 90","DOI":"10.1016\/S0920-9964(03)80477-2"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0164|cit164","unstructured":"Keefe RS Seiden LJ Christensen B Yurgelun-Todd DA Lewine RR Sitskoorn M Treatment of neurocognitive deficits with olanzapine or low-dose haloperidol in first episode psychosis 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico 2000"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0165|cit165","unstructured":"Keefe RS Seidman LJ Hamer RM Todd DY Christensen B Sitskoorn MM Neurocognition after two years olanzapine or low-dose haldol in fe psychosis 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA 2003"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0166|cit166","unstructured":"Keefe RS Seidman LJ Hamer RM Todd DY Christensen B Sitskoorn MM Neurocognition after two years olanzapine or low-dose haldol in fe psychosis 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA 2003"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0920-9964(03)80491-7","article-title":"Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia","volume":"60","author":"Lieberman","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0168|cit168","unstructured":"Lieberman J Sanger T Tohen M First Episode Collaborative Study Group Olanzapine and haloperidol treatment of first epiode schizophrenia and schizoaffective disorder: 12 week outcome of a two year randomized double blind trial 2nd International Conference on Early Psychosis; 2000 Mar 31 - Apr 2, New York, USA 2000"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0169|cit169","unstructured":"Lieberman J Tohen M McEvoy J Sanger T Keefe R Charles C Olanzapine versus haldoperidol in the treatment of first episode phychosis 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico 2000"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0170|cit170","unstructured":"Lieberman JA Charles C Sharma T Zipursky RB Hamer RM Tollefson GD Effect of olanzapine versus haloperidol on brain pathomorphology in first-episode psychosis 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA 2003"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0171|cit171","unstructured":"Lieberman JA Schneider LS McEroy J Pariot P Stroup S Adiao J Effectiveness trials of antipsychotic drugs 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA 2002"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0172|cit172","unstructured":"Lieberman JA Schneider LS McEroy J Pariot P Stroup S Adiao J Effectiveness trials of antipsychotic drugs Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA Marathon Multimedia 2001 21093232"},{"issue":"10","key":"10.1002\/14651858.CD013425.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1176\/appi.ajp.160.10.1748","article-title":"Schizophrenia, VI: Treatments","volume":"160","author":"Lieberman","year":"2003","journal-title":"American Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD013425.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1176\/appi.ajp.160.8.1396","article-title":"Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol","volume":"160","author":"Lieberman","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0175|cit175","unstructured":"Lieberman JA Research gaps and current research initiatives to improve the treatment of schizophrenia 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA 2003"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0176|cit176","doi-asserted-by":"crossref","unstructured":"McEvoy J Lieberman JA Perkins D Hamer RM Sharma T Zipursky R Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia Schizophrenia Research 2003 313","DOI":"10.1016\/S0920-9964(03)80257-8"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0177|cit177","unstructured":"McEvoy JP Lieberman JA Perkins DO Hamer RM Sharma T Zipursky RB Long-term olanzapine treatment versus haloperidol in first-episode psychosis 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA 2003"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0178|cit178","first-page":"195","article-title":"Cognitive effects of clozapine and olanzapine in patients with chronic schizophrenia","volume":"3 Suppl 1","author":"Sharma","year":"2002","journal-title":"Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1016\/S0924-977X(03)91655-5","article-title":"Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia","volume":"13","author":"Sharma","year":"2003","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0180|cit180","unstructured":"Sharma T The acute and long-term efficacy of olanzapine in first-episode psychotic disorders: a randomised double-blind comparison with haloperidol National Research Register 2000"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0920-9964(03)80215-3","article-title":"Clinical correlates of weight gain in first episode psychosis patients treated with olanzapine","volume":"60","author":"Zipursky","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0183|cit183","unstructured":"Zipursky RB Hongbin G Green AI Centorrina F Glick ID Lieberman JA Clinical correlates of weight gain in first-episode patients on olanzapine 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA 2003"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0184|cit184","doi-asserted-by":"crossref","unstructured":"Breier A Young C Purdon SE Gold JM Keefe RSE A one year double-blind comparision of the neurocognitive efficacy of olanzapine, risperidone and haloperidol in patients with schizophrenia Schizophrenia Research March 29 - April 2003; Colorado Springs, CO 2003","DOI":"10.1016\/S0920-9964(03)80434-6"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2005.07.038","article-title":"One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia","volume":"81","author":"Keefe","year":"2006","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0186|cit186","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1471-244X-9-44","article-title":"Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy","volume":"9","author":"Lipkovich","year":"2009","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0187|cit187","first-page":"369","article-title":"Patient perspectives on antipsychotic treatments and their association with clinical outcomes","volume":"4","author":"Liu-Seifert","year":"2010","journal-title":"Patient Preference and Adherence"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/ebmh.9.3.71","article-title":"Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks","volume":"9","author":"Lysaker","year":"2006","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0189|cit189","first-page":"1","article-title":"Efficacy study of switching stabilized schizophrenic patients from conventional to atypical antipsychotic treatment","volume":"NA","year":"2007","journal-title":"Unpublished report"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0190|cit190","first-page":"254","article-title":"Olanzapina versus haloperidol: efectividad en la funcionalidad y estado de salud en una muestra de pacientes venezolanos con esquizofrenia","volume":"9","author":"Adrianz\u00e9n","year":"2008","journal-title":"ERTE"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0191|cit191","unstructured":"Olanzapine for schizophrenia: a cost benefit study STUDY F1D-GW-S034 2006"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0192|cit192","unstructured":"Comparative efficacy of olanzapine and haloperidol treatment episode psychosis patients \u4e2d\u5916\u5065\u5eb7\u6587\u6458 [\u533b\u836f\u6708\u520a] 2008 5 4 269 70"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0193|cit193","first-page":"493","article-title":"A randomized, double-blind study of olanzapine vs haloperidol in the treatment of primary negative symptoms in schizophrenia","volume":"31","author":"Lindenmayer","year":"2005","journal-title":"Schizophrenia Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4088\/JCP.v68n0303","article-title":"A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia","volume":"68","author":"Lindenmayer","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0195|cit195","unstructured":"Effect of olanzapine and haloperidol in the treatment of Schizophrenia [Google Translate] Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66] 2010 22 14 1782, 1835"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0196|cit196","unstructured":"Controlled study of olanzapine and haloperidol in schizophrenia cognitive function Journal of Medical Forum [\u533b\u836f\u8bba\u575b\u6742\u5fd7] 2011 32 13 126 8"},{"issue":"04","key":"10.1002\/14651858.CD013425.pub2-BIB0197|cit197","first-page":"396","article-title":"Senile controlled study of olanzapine and haloperidol in schizophrenia treatment [Google Translate]","volume":"-","year":"2012","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0198|cit198","first-page":"35","article-title":"\u5965\u6c2e\u5e73\u4e0e\u6c1f\u54cc\u5576\u9187\u6cbb\u7597\u9996\u53d1\u7cbe\u795e\u75c5\u60a3\u8005\u7684\u7597\u6548\u5bf9\u6bd4\u7814\u7a76","volume":"11","year":"2012","journal-title":"\u5065\u5eb7\u5fc5\u8bfb\uff08\u4e2d\u65ec\u520a\uff09"},{"issue":"8","key":"10.1002\/14651858.CD013425.pub2-BIB0199|cit199","first-page":"723","article-title":"The efficacy and quality of life of patients with schizophrenia, olanzapine","volume":"14","year":"2005","journal-title":"Chinese Journal of Behavioral Medical Science [\u4e2d\u56fd\u884c\u4e3a\u533b\u5b66\u79d1\u5b66]"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0200|cit200","doi-asserted-by":"crossref","unstructured":"Malyarov S Dzub G Comparative assessment of the positive and negative symptom dynamics in schizophrenic patients treated with atypical antipsychotics or haloperidol Journal of the European College of Neuropsychopharmacology 1999 S296 21040726","DOI":"10.1016\/S0924-977X(99)80369-1"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0201|cit201","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4103\/2279-042X.128142","article-title":"Onset of action of atypical and typical antipsychotics in the treatment of acute psychosis","volume":"2","author":"Mousavi","year":"2013","journal-title":"Journal of Research in Pharmacy Practice"},{"issue":"12","key":"10.1002\/14651858.CD013425.pub2-BIB0202|cit202","first-page":"47","article-title":"Depressive symptomatology: comparative evaluation of typical versus atypical antipsychotics in schizophrenic patients using MADRS scale","volume":"6","author":"Bhardwaj","year":"2016","journal-title":"Indian Journal of Applied Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0203|cit203","first-page":"S127","article-title":"Conical and quality-of-life outcomes associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: results from a US random study","volume":"Suppl 1","author":"Namjoshi","year":"2002","journal-title":"International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0204|cit204","doi-asserted-by":"crossref","unstructured":"Namjoshi M Young CA Huang L Edgell E Breier A Cost-effectiveness of olanzapine compared to risperidone and haloperidol in the treatment of patients with schizophrenia: results from a U.S. randomized controlled trial Schizophrenia Research International Congress on Schizophrenia Research, March 29-April 2, 2003, Colorado Springs, CO 2003","DOI":"10.1016\/S0920-9964(03)80500-5"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0920-9964(03)80500-5","article-title":"Cost-effectiveness of olanzapine compared to risperidone and haloperidol in the treatment of patients with schizophrenia: results from a U.S. randomized controlled trial","volume":"60","author":"Namjoshi","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0206|cit206","doi-asserted-by":"crossref","unstructured":"Namjoshi M Young CM Huang L Edgell ET Breier A Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: Results from a U.S. randomized controlled trial European Neuropsychopharmacology 2002 Suppl 3 S315","DOI":"10.1016\/S0924-977X(02)80471-0"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0207|cit207","first-page":"113","article-title":"Large dose of olanzapine in the ictus treatment of agitated symptoms of schizophrenia","volume":"11","author":"Pan","year":"2005","journal-title":"Journal of Clinical Psychosomatic Diseases [\u4e34\u5e8a\u5fc3\u8eab\u75be\u75c5\u6742\u5fd7]"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0208|cit208","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cct.2011.04.008","article-title":"The GiSAS study: Rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia","volume":"32","author":"Parabiaghi","year":"2011","journal-title":"Contemporary Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0209|cit209","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/acps.12468","article-title":"Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol","volume":"133","author":"Parabiaghi","year":"2016","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0210|cit210","volume-title":"Aripiprazole, Olanzapine and Haloperidol in the Long-Term Treatment of Schizophrenia: The Rationale and Development of the GiSAS Pragmatic Randomized Controlled Trial, a Consideration and Empirical Study of Factors Associated With Recruitment (the GiSAS S","author":"Parabiaghi","year":"2012"},{"issue":"16","key":"10.1002\/14651858.CD013425.pub2-BIB0211|cit211","first-page":"139","article-title":"Olanzapine analysis of the effect of treatment of mental illness [Google Translate]","volume":"NA","year":"2013","journal-title":"\u4e2d\u5916\u533b\u5b66\u7814\u7a76"},{"issue":"10","key":"10.1002\/14651858.CD013425.pub2-BIB0212|cit212","first-page":"1011","article-title":"A comparative trial of olanzapine versus haloperidol in the treatment of schizophrenia","volume":"12","author":"Qin","year":"2006","journal-title":"Hebei Medicine [\u6cb3\u5317\u533b\u5b66]"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-0031-1280793","article-title":"Body mass index increase, serum leptin, adiponectin, neuropeptide Y and lipid levels during treatment with olanzapine and haloperidol","volume":"44","author":"Raposo","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0214|cit214","unstructured":"Davis L Sheikh J Rosenheck R Frecska E Douyon R Evans D To determine if olanzapine is more cost effective than haloperidol for the treatment of schizophrenia\/The clinical and economic impact of olanzapine in the treatment of schizophrenia National Institutes of Health (http:\/\/www.clinicaltrials.gov\/)"},{"issue":"9","key":"10.1002\/14651858.CD013425.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1001\/jama.291.9.1065-c","article-title":"Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial","volume":"291","author":"Glazer","year":"2004","journal-title":"JAMA"},{"issue":"20","key":"10.1002\/14651858.CD013425.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.290.20.2693","article-title":"Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial","volume":"290","author":"Rosenheck","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1097\/01.yic.0000405861.38270.24","article-title":"Antipsychotic use associated with metabolic & weight changes in schizophrenia","volume":"26","author":"Saddichha","year":"2011","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1097\/01.yic.0000405877.64343.71","article-title":"Hypertension, diabetes and cardiometabolic changes associated with antipsychotic use in schizophrenia","volume":"26","author":"Saddichha","year":"2011","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0219|cit219","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/jcp.0b013e3181602fe6","article-title":"Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol","volume":"28","author":"Saddichha","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0220|cit220","article-title":"Obesity, diabetes and hypertension associated with antipsychotic use in drug naive schizophrenia","volume":"-","author":"Saddichha","year":"2010","journal-title":"-"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0221|cit221","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1600-0447.2008.01158.x","article-title":"Diabetes and schizophrenia\u2013effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia","volume":"117","author":"Saddichha","year":"2008","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"11","key":"10.1002\/14651858.CD013425.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.4088\/JCP.v68n1120","article-title":"Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study","volume":"68","author":"Saddichha","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1-3","key":"10.1002\/14651858.CD013425.pub2-BIB0223|cit223","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.schres.2008.05.023","article-title":"Erratum to \u201cMetabolic syndrome in first episode schizophrenia\u2014A randomized double-blind controlled, short-term prospective study\u201d[Schizophrenia Research 101 (2008) 266272]","volume":"104","author":"Saddichha","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"1-3","key":"10.1002\/14651858.CD013425.pub2-BIB0224|cit224","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.schres.2008.01.004","article-title":"Metabolic syndrome in first episode schizophrenia\u2014a randomized double-blind controlled, short-term prospective study","volume":"101","author":"Saddichha","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"3-4","key":"10.1002\/14651858.CD013425.pub2-BIB0225|cit225","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/15504263.2015.1113761","article-title":"Substance use in patients with first-episode psychosis: is gender relevant?","volume":"11","author":"Arranz","year":"2015","journal-title":"Journal of Dual Diagnosis"},{"issue":"2-3","key":"10.1002\/14651858.CD013425.pub2-BIB0226|cit226","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.psychres.2012.07.005","article-title":"One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis","volume":"200","author":"San","year":"2012","journal-title":"Psychiatry Research"},{"issue":"10","key":"10.1002\/14651858.CD013425.pub2-BIB0227|cit227","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1176\/appi.ajp.2007.06091515","article-title":"Social cognition and neurocognition: effects of risperidone, olanzapine, and haloperidol","volume":"164","author":"Sergi","year":"2007","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0228|cit228","first-page":"26","article-title":"A control study on olanzapine versus haloperidol in the treatment of female schizophrenic","volume":"22","year":"2009","journal-title":"Sichuan Mental Health [\u56db\u5ddd\u7cbe\u795e\u536b\u751f]"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/s12888-017-1562-1","article-title":"Potential diagnostic markers of olanzapine efficiency for acute psychosis: a focus on peripheral biogenic amines","volume":"17","author":"Taraskina","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0230|cit230","unstructured":"Alan B Hamilton SH Comparative efficacy of olanzapine and haloperidol for patients with treatment resistant schizophrenia 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany 1999 144"},{"issue":"5 Pt 2","key":"10.1002\/14651858.CD013425.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2165\/00019053-199813050-00010","article-title":"Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine and haloperidol","volume":"13","author":"Almond","year":"1998","journal-title":"Pharmacoeconomics"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0920-9964(97)88781-6","article-title":"Sex and neuroendocrine differences in response to treatment with olanzapine: a preliminary analysis","volume":"29","author":"Andersen","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0233|cit233","doi-asserted-by":"crossref","unstructured":"Andersen SW Tollefson GD Sanger T Depressive signs and symptoms in schizophrenia:a prospective blinded trial of olanzapine and haloperidol APA Annual Meeting; May 15-20; Washington DC; USA 1999","DOI":"10.1016\/S0924-977X(98)80375-1"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0234|cit234","unstructured":"Baker R W Julier B Stauffer V Manic-like symptoms in schizophrenic patients treated with olanzapine, haloperidol and placebo 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany 2001"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013425.pub2-BIB0235|cit235","first-page":"A60","article-title":"Factors influencing weight change in patients with schizophrenia treated with olanzapine verus haloperidol or risperidone","volume":"14","author":"Basson","year":"2000","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0236|cit236","doi-asserted-by":"crossref","unstructured":"Beasley C Tran P Beuzen JN Tamura R Dellva MA Bailey J Olanzapine versus haloperidol: long-term results of the multi-center international trial XXth Collegium Internationale Neuro-psychopharmacologicum; June 23-27; Melbourne; Australia 1996","DOI":"10.1016\/0924-977X(96)87576-6"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD013425.pub2-BIB0237|cit237","first-page":"13","article-title":"Safety of olanzapine","volume":"58","author":"Tollefson","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0920-9964(97)88362-4","article-title":"The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia","volume":"29","author":"Beasley","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0239|cit239","unstructured":"Beasley CM Tollefson GD Dellva MA Tamura R Glazer WM Morgenstern H The differential risk of tardive dyskinesia with olanzapine 151st Annual Meeting of American Psychiatric Association; May 30 - June 4; Toronto; ON, Canada 1998"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0240|cit240","first-page":"19","article-title":"Safety of olanzapine","volume":"15","author":"Beasley","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0241|cit241","first-page":"19","article-title":"Safety of olanzapine","volume":"15","author":"Beasley","year":"1997","journal-title":"Journal of Clinical Psychiatry Monograph"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0242|cit242","doi-asserted-by":"crossref","unstructured":"Brecher M Risperidone versus olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum; July 12-16; Glasgow; Scotland, UK 1998","DOI":"10.1016\/S0924-977X(98)80413-6"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0006-3223(99)00040-2","article-title":"The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, prediction of outcome","volume":"46","author":"Breier","year":"1999","journal-title":"Biological Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0006-3223(98)00291-1","article-title":"Comparative efficacy of olanzapine and haloperidol with treatment-resistant schizophrenia","volume":"45","author":"Breier","year":"1999","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0245|cit245","unstructured":"Breier AF Hamilton SH Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia APA Annual Meeting, May 15-20, 1999, Washington, DC 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0246|cit246","unstructured":"Burns PR Reams SG Sanger TM Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders 9th Biennial Winter Workshop on Schizophrenia, February 7-13, 1998-Davos, Switzerland 1998 ABSTRACT REF:PT07052"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0247|cit247","unstructured":"Burns PR Reams SG Sanger TM Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum. Glasgow, Scotland, UK"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0248|cit248","unstructured":"Cohen LS Goldstein JM Lee H Tohen M Andersen S Tollefson GD Sex and neuroendocrine differences following treatment with typical and atypical antipsychotics 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998 1998"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0249|cit249","doi-asserted-by":"crossref","unstructured":"Conley RR Brecher M The Risperidone\/Olanzapine Study Group Riasperidone versus olanzapine in patients with schizophrenia or schizoaffective disorders European College of Neurpsychopharmacology Meeting; October 31-November 4; Paris; France 1998","DOI":"10.1016\/S0924-977X(98)80413-6"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0924-977X(97)88650-6","article-title":"Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi-center international trial","volume":"7","author":"Crawford","year":"1997","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"P.2.015","DOI":"10.1016\/S0924-977X(97)88650-6","article-title":"Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi-center international trial","volume":"7","author":"Crawford","year":"1997","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013425.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1016\/S0924-977X(98)80387-8","article-title":"Prolactin levels in olanzapine versus typical and atypical antipsychotics","volume":"8","author":"David","year":"1998","journal-title":"European Neuropsychopharmacology"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0920-9964(97)88690-2","article-title":"Prolactin levels in olanzapine versus typical and atypical antipsychotics","volume":"29","author":"David","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0254|cit254","doi-asserted-by":"crossref","unstructured":"Dellva M Satterlee W Tran P Beasley C Greaney M Tollefson G Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in acute treatment 9th Congress of the European College of Neuropsychopharmacology, Amsterdam, The Netherlands 1996","DOI":"10.1016\/0924-977X(96)83226-3"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0255|cit255","unstructured":"Dellva MA Beasley CM Kuntz AJ Tamura RN Glazer WM Morgenstern H What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine? 11th Annual Meeting of the American Association for Geriatric Psychiatry; San Diego; California 1998"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0256|cit256","unstructured":"Dellva MA Beasley CM Tamura RN Tollefson GD What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine? Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum; July 12-16; Glasgow; Scotland, UK 1998"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1176\/ps.48.12.1571","article-title":"Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia","volume":"48","author":"Dellva","year":"1997","journal-title":"Psychiatric Services"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0258|cit258","doi-asserted-by":"crossref","unstructured":"Edgell ET Hamilton SH Revicki DA Genduso LA Tollefson GD Costs of olanzapine treatment compared with haloperidol for schizophrenia: results from a randomized clinical trial Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum; July 12-16; Glasgow; Scotland, UK 1998","DOI":"10.1016\/S0924-977X(98)80406-9"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013425.pub2-BIB0259|cit259","first-page":"S155","article-title":"Effect of long term olanzapine treatment on weight change in schizophrenia","volume":"3","author":"Gilmore","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013425.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"S305","DOI":"10.1016\/S0924-977X(00)80346-6","article-title":"Effect of long term olanzapine treatment on weight change in schizophrenia","volume":"10","author":"Gilmore","year":"2000","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0261|cit261","first-page":"100","article-title":"Acute double-blind comparison of olanzapine and haloperidol in schizophrenia patients age >= 60","volume":"10","author":"Gilmore","year":"2002","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0262|cit262","first-page":"177","article-title":"Improvement in quality of life and depressive symptoms in schizophrenic patients is associated with robust acute treatment response of olanzapine versus haloperidol","volume":"3 Suppl 1","author":"Gilmore","year":"2002","journal-title":"Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0263|cit263","first-page":"177","article-title":"Rigorous criteria for treatment response differentiated efficacy of olanzapine versus haloperidol in patients with schizophrenia","volume":"3 Suppl 1","author":"Gilmore","year":"2002","journal-title":"Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD013425.pub2-BIB0264|cit264","first-page":"50","article-title":"Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia","volume":"58","author":"Glazer","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0165-1781(02)00028-8","article-title":"Sex differences in clinical response to olanzapine compared with haloperidol","volume":"110","author":"Goldstein","year":"2002","journal-title":"Psychiatry Research"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013425.pub2-BIB0266|cit266","first-page":"6","article-title":"Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial","volume":"62","author":"Gomez","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0267|cit267","doi-asserted-by":"crossref","unstructured":"Grainger D Hamilton SH Genduso LA Revicki DA Medical resource use and work and social outcomes for olanzapine compared with haloperidol in the treatment of schizophrenia 21st Congress of Collegium Internationale Neuro-psychopharmacologicum; Glasgow; Scotland, UK 1998","DOI":"10.1016\/S0920-9964(97)88677-X"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0268|cit268","unstructured":"Gregor K Hamilton S Edgell E Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany 1999 152"},{"issue":"Number 1 - Spec","key":"10.1002\/14651858.CD013425.pub2-BIB0269|cit269","first-page":"189","article-title":"An economic comparison of olanzapine versus haloperidol in the treatment of schizophrenia in France","volume":"41","author":"Gregor","year":"2000","journal-title":"Schizophrenia Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013425.pub2-BIB0270|cit270","first-page":"S161","article-title":"An economic comparison of olanzapine versus haloperidol in the treatment of schizophrenia in France","volume":"3","author":"Gregor","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013425.pub2-BIB0271|cit271","first-page":"S11","article-title":"Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol","volume":"9","author":"Gregor","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013425.pub2-BIB0272|cit272","first-page":"S11","article-title":"Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol","volume":"9","author":"Gregor","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"S289","DOI":"10.1016\/S0924-977X(99)80349-6","article-title":"Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol","volume":"9","author":"Gregor","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0274|cit274","first-page":"189","article-title":"Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol","volume":"1","author":"Gregor","year":"2000","journal-title":"Schizophrenia Research (10th Biennial Winter Workshop on Schizophrenia; 2000 Feb 5-11; Davos, Switzerland)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0275|cit275","doi-asserted-by":"crossref","unstructured":"Hamilton S Breier A David S Comparative efficacy of olanzapine and haloperidol for patients with treatment resistant schizophrenia 11th Congress of The European College of Neuropsychopharmacology; 1998 Oct 31- Nov 4; Paris, France 1998","DOI":"10.1016\/S0924-977X(98)80383-0"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0276|cit276","doi-asserted-by":"crossref","unstructured":"Hamilton S Revicki D Genduso LA Tollefson GD Cost of olanzapine treatment compared with haloperidol for schizophrenia: results from a randomized clinical trial 151st Annual Meeting of the American Psychiatric Association; May 30-June 4; Toronto; ON, Canada 1998","DOI":"10.1016\/S0924-977X(98)80406-9"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013425.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1016\/S0924-977X(98)80383-0","article-title":"Comparative efficacy of olanzapine and patients with treatment-resistant schizophrenia","volume":"8","author":"Hamilton","year":"1998","journal-title":"European Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00004850-200015050-00001","article-title":"Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample","volume":"15","author":"Hamilton","year":"2000","journal-title":"International Clinical Psychopharmacology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013425.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1016\/S0924-977X(98)80406-9","article-title":"Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomized clinical trial","volume":"8","author":"Hamilton","year":"1998","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0280|cit280","unstructured":"Hamilton SH Genduso LA Haley JC Revicki DA Medical resource use and socioeconomics in the treatment of schizophrenia: olanzapine compared with haloperidol 10th European College of Neuropsychopharmacology Congress; Sep 13-17; Vienna; Austria 1997"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0920-9964(97)88677-X","article-title":"Medical resource use and work and social outcomes for olanzapine compared with haloperidol in the treatment of schizophrenia and other psychotic disorders","volume":"29","author":"Hamilton","year":"1998","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00019053-199915050-00005","article-title":"Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia - results from a randomised clinical trial","volume":"15","author":"Hamilton","year":"1999","journal-title":"Pharmacoeconomics"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0920-9964(97)88678-1","article-title":"Costs of olanzapine treatment compared with haloperidol for schizophrenia: results from a randomized clinical trial","volume":"29","author":"Hamilton","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1016\/S0920-9964(03)80170-6","article-title":"Differential rate of weight gain present among patients treated with olanzapine","volume":"60","author":"Jaton","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0285|cit285","first-page":"233","article-title":"Continued improvement in quality of life despite weight change during olanzapine treatment","volume":"1-2 Suppl","author":"Javor","year":"2001","journal-title":"Schizophrenia Research (8th International Congress on Schizophrenia Research; 2001 Apr 28 - May 2; British Columbia, Canada)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0286|cit286","unstructured":"Johnstone BM Obenchain RL Croghan TW Tunis SL Kniesner TJ To evaluate the cost-effectiveness of olanzapine compared to haloperidol for schizophrenia 151st Annual Meeting of American Psychiatric Association; May 30-June 4; Toronto; ON, Canada 1998"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013425.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1016\/S0924-977X(98)80404-5","article-title":"Intent-to-treat analysis of repeated measures data from a randomized clinical trial comparing the cost and effectiveness of treatment for schizophrenia with olanzapine or haloperidol","volume":"8","author":"Johnstone","year":"1998","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/gps.1007","article-title":"Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial","volume":"18","author":"Kennedy","year":"2003","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0289|cit289","unstructured":"Kinon B Basson B Tollefson GD Gender specific prolactin olanzapine versus haloperidol in schizophrenia American Psychiatric Association, Toronto, Canada MAy 30- June 4 1998"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013425.pub2-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1016\/S0924-977X(98)80361-1","article-title":"Predictors of weight gain during olanzapine treatment","volume":"8","author":"Kinon","year":"1998","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4088\/JCP.v62n0204","article-title":"Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia","volume":"62","author":"Kinon","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Number 1 - Spec","key":"10.1002\/14651858.CD013425.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0920-9964(00)90780-1","article-title":"Effect of long-term olanzapine treatment on weight change in schizophrenia","volume":"41","author":"Kinon","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0293|cit293","unstructured":"Kinon BJ Basson MS Tollefson GD Gender-specific prolactin response to treatment with olanzapine vs. haloperidol in schizophrenia Poster presented at the 9th Biennial European Winter Workshop on Schizophrenia; 1998 February 7-13, Davos, Switzerland 1998"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0294|cit294","doi-asserted-by":"crossref","unstructured":"Kinon BJ Gilmore JA Gottschalk LA Continued improvement in quality of life despite weight change during olanzapine treatment 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico 2000","DOI":"10.1016\/S0924-977X(00)80346-6"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013425.pub2-BIB0295|cit295","first-page":"S154","article-title":"Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine","volume":"3","author":"Kinon","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013425.pub2-BIB0296|cit296","first-page":"17","article-title":"Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia","volume":"62","author":"Kinon","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0297|cit297","unstructured":"Kuntz AJ Sanger TM Beasley CM Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders 11th Annual Meeting of the American Association for Geriatric Psychiatry, San Diego, California 1998"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013425.pub2-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/S0924-977X(98)80374-X","article-title":"Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders","volume":"8","author":"Lane","year":"1998","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0299|cit299","first-page":"281","article-title":"An economic comparison of olanzapine versus haloperidol in the treatment of schizophrenia in France","volume":"25","author":"Le Pen","year":"1999","journal-title":"Encephale"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0300|cit300","doi-asserted-by":"crossref","unstructured":"Lu Y Sanger T Beasley C Tran P Olanzapine in the treatment of schizoaffective disorder 9th Congress of the European College of Neuropsychopharmacology; Amsterdam; The Netherlands 1996","DOI":"10.1016\/0924-977X(96)83034-3"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013425.pub2-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1016\/S0924-977X(98)80384-2","article-title":"Long-term efficacy and safety of olanzapine in patients with inadequate initial response to haloperidol or olanzapine","volume":"8","author":"Mallinckrodt","year":"1998","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0302|cit302","unstructured":"Mallinckrodt CH David SR Burns PR Breier A Long-term efficiacy and safety of olanzapine in patients with inadequate initial response to haloperidol or olanzapine Schizophrenia Research (7th International Congress on Schizophrenia Research, 1999 Apr 17-21, Santa Fe, New Mexico, USA) 1999 288"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0303|cit303","unstructured":"Martin C Genduso L Revicki D Hamilton S Tran P Beasley C Impact of olanzapine on patient quality of life in schizophrenia Xth World Congress of Psychiatry; August 23-28; Madrid; Spain 1996"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0304|cit304","unstructured":"Martin C Impact of olanzapine on quality of life in schizophrenia 8th Congress of the Association of European Psychiatrists; Jul 7-12; London; England, UK 1996"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0920-9964(00)90770-9","article-title":"Change in extrapyramidal symptoms with olanzapine in comparison with other antipspychotic agents","volume":"41","author":"Meehan","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0306|cit306","unstructured":"Naber D Evidence of efficacy of neuroleptics in effective versus negative symptoms 10th European College of Neuropsychopharmacology Congress; Sep 13-17; Vienna; Austria 1997"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0307|cit307","unstructured":"Patel B Kurtz DL Callaghan JT Bergstrom RF Effect of smoking and gender on population pharmacokinetics of olanzapine American Psychiatric Association, 149th Annual Meeting; May 4-9 1996"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF02245615","article-title":"Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - a 123I IBZM single photon emission tomography (SPET) study","volume":"124","author":"Pilowsky","year":"1996","journal-title":"Psychopharmocology"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0920-9964(97)88686-0","article-title":"Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders","volume":"29","author":"Reams","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0310|cit310","unstructured":"Revicki D Genduso LA Hamilton SL Martin C Reblando J Tran PV Quality of life outcomes for olanzapine and haloperidol treatment for schizophrenia and related psychotic disorders American Psychiatric Association, 149th Annual Meeting; May 4-9 1996"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0311|cit311","first-page":"708","article-title":"Quality of life outcomes for olanzapine and haloperidol treatment for schizophrenia and other psychotic disorders: results of an international randomized clinical trial","volume":"6","author":"Revicki","year":"1997","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0312|cit312","unstructured":"Revicki DA Quality of life and re-integration of chronically ill patients 9th Congress of the Association of European Psychiatrists; Copenhagen 1998 Abstract number:Lilly SAT1-5"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1023\/A:1008958925848","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders. Quality of life outcomes of a randomized clinical trial","volume":"8","author":"Revicki","year":"1999","journal-title":"Quality of Life Research"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013425.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1016\/S0924-977X(98)80385-4","article-title":"Olanzapine versus haloperidol treatment in first-episode psychosis","volume":"8","author":"Sanger","year":"1998","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0315|cit315","doi-asserted-by":"crossref","unstructured":"Sanger T Lieberman JA Tohen M Tollefson GD Olanzapine versus haloperidol in the treatment of first episode psychosis Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum; July 12-16; Glasgow; Scotland, UK 1998","DOI":"10.1016\/S0920-9964(97)88685-9"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0316|cit316","doi-asserted-by":"crossref","unstructured":"Sanger T Lieberman JA Tohen M Tollefson GD Olanzapine versus haloperidol in the treatment of psychosis 151st Annual Meeting of the American Psychiatric Association; May 30-June 4; Toronto; ON, Canada 1998","DOI":"10.1016\/S0920-9964(97)88685-9"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0317|cit317","doi-asserted-by":"crossref","unstructured":"Sanger T Tollefson GD Lieberman JA Tohen M Olanzapine versus haloperidol in the treatment of first-episode psychosis American Psychiatric Association, 150th Annual Meeting; San Diego; CA, USA 1997","DOI":"10.1016\/S0920-9964(97)82552-2"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1176\/ajp.156.1.79","article-title":"Olanzapine versus haloperidol treatment in first-episode psychosis","volume":"156","author":"Sanger","year":"1999","journal-title":"American Journal of Psychiatry"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0920-9964(97)88685-9","article-title":"Olanzapine versus haloperidol treatment of first-episode psychosis","volume":"29","author":"Sanger","year":"1998","journal-title":"Schizophrenia Research"},{"issue":"1,2","key":"10.1002\/14651858.CD013425.pub2-BIB0320|cit320","first-page":"163","article-title":"Olanzapine, a new \"atypical\" antipsychotic","volume":"15","author":"Satterlee","year":"1995","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0321|cit321","doi-asserted-by":"crossref","unstructured":"Satterlee WG Beasley CM Tran PV Tamura RN Krueger JA Tollefson GD Olanzapine versus haloperidol - results of a large multi-center international trial American Psychiatric Association, 149th Annual Meeting; May 4-9 1996","DOI":"10.1016\/0924-977X(96)87576-6"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0322|cit322","unstructured":"Satterlee WG Beasley CM Tran PV Tamura RN Krueger JA Tollefson GD Olanzapine versus haloperidol in a large international trial Xth World Congress of Psychiatry; August 23-28; Madrid; Spain 1996"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0323|cit323","first-page":"522","article-title":"Long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol","volume":"32","author":"Street","year":"1996","journal-title":"Psychopharmacology Bulletin"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0920-9964(97)88754-3","article-title":"What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine?","volume":"29","author":"Tamura","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0325|cit325","unstructured":"Tohen M Sanger T Tollefson GD McElroy SL Olanzapine versus haloperidol in the treatment of schizoaffective bipolar patients American Psychiatric Association, 150th Annual Meeting. San Diego, CA, USA 1997"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0326|cit326","unstructured":"Tohen M Sanger T Tollefson GD McElroy SL Olanzapine versus haloperidol in the treatment of schizoaffective bipolar patients American Psychiatric Association, 150th Annual Meeting; San Diego; CA, USA 1997"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0327|cit327","unstructured":"Tohen M Sanger T Tollefson GD Gender differences in the response of olanzapine versus haloperidol in the treatment of first-episode psychosis American Psychiatric Association, 150th Annual Meeting; San Diego; CA, USA 1997"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0328|cit328","doi-asserted-by":"crossref","unstructured":"Tohen MF Zhang F Sanger TM Gannon KS Tollefson GD Olanzapine versus haloperidol in schizoaffective bipolar disorder: a repeated-measures analysis APA Annual Meeting, May 15-20, Washington, DC 1999","DOI":"10.1016\/S0924-977X(99)80225-9"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0329|cit329","first-page":"401","article-title":"Olanzapine versus haloperidol: acute results of the multicenter international trial","volume":"32","author":"Tollefson","year":"1996","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0330|cit330","unstructured":"Tollefson G Beasley C Tran P Sanger T Olanzapine: an exciting atypical antipsychotic: the clinical experience 8th European College of Neuropsychopharmacology Congress; Sep 30-Oct 4; Venice; Italy 1995"},{"issue":"9","key":"10.1002\/14651858.CD013425.pub2-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1176\/ajp.154.9.1248","article-title":"Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol","volume":"154","author":"Tollefson","year":"1997","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial","volume":"154","author":"Tollefson","year":"1997","journal-title":"American Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD013425.pub2-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0920-9964(96)85440-5","article-title":"Olanzapine versus haloperidol: results of the multi-center international trial","volume":"18","author":"Tollefson","year":"1996","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0334|cit334","first-page":"192","article-title":"Olanzapine in the treatment of schizoaffective disorder","volume":"24","author":"Tollefson","year":"1997","journal-title":"Schizophrenia Research (Special Issue) - The VIth International Congress on Schizophrenia Research, Colorado Springs, CO, USA; April 12-16, 1997"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0335|cit335","first-page":"192","article-title":"Olanzapine in the treatment of schizoaffective disorder","volume":"24","author":"Tollefson","year":"1997","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0336|cit336","unstructured":"Tollefson GD Lu Y A blinded trial on the course and relationship of depressive symptoms in schizophrenia American Psychiatric Association, 150th Annual Meeting; San Diego; CA, USA 1997"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0337|cit337","doi-asserted-by":"crossref","unstructured":"Tollefson GD Lu Y Comorbid mood disturbance in schizophrenia 9th European College of Neuropsychopharmacology Congress; Sep 21-25; Amsterdam; The Netherlands 1996","DOI":"10.1016\/0924-977X(96)87588-2"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0338|cit338","doi-asserted-by":"crossref","unstructured":"Tollefson GD Lu Y Comorbid mood disturbance in schizophrenia XXth Collegium Internationale Neuro-psychopharmacologicum; June 23-27; Melbourne; Australia 1996","DOI":"10.1016\/0924-977X(96)87588-2"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0339|cit339","first-page":"192","article-title":"Comorbid mood disturbance in schizophrenia","volume":"24","author":"Tollefson","year":"1997","journal-title":"Schizophrenia Research (Special Issue) - The VIth International Congress on Schizophrenia Research, Colorado Springs, CO, USA; April 12-16, 1997"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0340|cit340","first-page":"191","article-title":"Comorbid mood disturbance in schizophrenia","volume":"24","author":"Tollefson","year":"1997","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0341|cit341","first-page":"73S","article-title":"Olanzapine versus haloperidol in the treatment of first episode psychosis","volume":"41","author":"Tollefson","year":"1997","journal-title":"Biological Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013425.pub2-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0924-977X(98)80375-1","article-title":"Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol","volume":"8","author":"Tollefson","year":"1998","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0924-977X(98)80375-1","article-title":"Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol","volume":"Suppl 2","author":"Tollefson","year":"1998","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0344|cit344","doi-asserted-by":"crossref","unstructured":"Tollefson GD Sanger TM Andersen SW Depressive signs and symptoms in schizophrenia:a prospective blinded trial of olanzapine and haloperidol 11th Congress of the European College of Neuropsychopharmacology; Paris; France 1998","DOI":"10.1016\/S0924-977X(98)80375-1"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0345|cit345","first-page":"193","article-title":"Olanzapine versus haloperidol in the treatment of first episode psychosis","volume":"24","author":"Tollefson","year":"1997","journal-title":"Schizophrenia Research (Special Issue) - The VIth International Congress on Schizophrenia Research, Colorado Springs, CO, USA; April 12-16, 1997"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0920-9964(97)82552-2","article-title":"Olanzapine versus haloperidol in the treatment of first-epsiode psychosis","volume":"24","author":"Tollefson","year":"1997","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/archpsyc.55.3.250","article-title":"Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol","volume":"55","author":"Tollefson","year":"1998","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0920-9964(98)00164-9","article-title":"Anxious-depressive symptoms in schizophrenia:a new treatment target for pharmacotherapy?","volume":"35 Suppl","author":"Tollefson","year":"1999","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0349|cit349","first-page":"20S","article-title":"Olanzapine versus risperidone in the treatment of psychosis. Preliminary report","volume":"41","author":"Tollefson","year":"1997","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0350|cit350","unstructured":"Tollefson GD A blinded trial on the course and relationship of depressive symptoms in schizophrenia Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum; July 12-16; Glasgow; Scotland, UK 1998"},{"issue":"3S","key":"10.1002\/14651858.CD013425.pub2-BIB0351|cit351","first-page":"S189","article-title":"Olanzapine: a novel antipsychotic with a broad spectrum profile","volume":"10","author":"Tollefson","year":"1994","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0352|cit352","doi-asserted-by":"crossref","unstructured":"Tollefson GD Treatment consideration for comorbid mood disorders in schizophrenic patients Sixth World Congress of Biological Psychiatry; June 22-27; Nice; France 1997","DOI":"10.1016\/S0006-3223(97)88032-8"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0353|cit353","doi-asserted-by":"crossref","unstructured":"Tran P Beasley C Street J Tamura R Dellva MA Graffeo K Olanzapine versus haloperidol: acute results of the multi-center international trial XXth Collegium Internationale Neuro-psychopharmacologicum; June 23-27; Melbourne; Australia 1996","DOI":"10.1016\/0924-977X(96)87575-4"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0354|cit354","doi-asserted-by":"crossref","unstructured":"Tran P Dellva M Tamura R Krueger J Beasley C Tollefson G Olanzapine versus haloperidol: results of the international trial 9th Congress of the European College of Neuropsychopharmacology; Amsterdam; The Netherlands 1996","DOI":"10.1016\/0924-977X(96)87575-4"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0355|cit355","unstructured":"Tran P Lu Y Sanger T Beasley C Tollefson G Olanzapine in the treatment of schizoaffective disorder 21st Congress of the Collegium Internationale Neuro-psychopharmacologicum; 1998 Jul 12-16; Glasgow, Scotland 1998 97055970"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0356|cit356","first-page":"527","article-title":"Olanzapine in the treatment of schizoaffective disorder","volume":"32","author":"Tran","year":"1996","journal-title":"Psychopharmacology Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0357|cit357","first-page":"527","article-title":"Olanzapine in the treatment of schizoaffective disorder","volume":"32","author":"Tran","year":"1996","journal-title":"Psychopharmacology Bulletin"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0920-9964(97)88684-7","article-title":"Olanzapine in the treatment of schizoaffective disorder","volume":"29","author":"Tran","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0359|cit359","unstructured":"Tran P Sanger TM Satterlee W Beasley CJ Tamura RN Tollefson GD Olanzapine vs haloperidol - results of a large multi-centre international trial Schizophrenia 1996: Breaking down the Barriers, 4th International Conference; October 6-9; Vancouver; BC, Canada 1996"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0360|cit360","doi-asserted-by":"crossref","unstructured":"Tran PV Dellva MA Satterlee WG Cousins LM Tollefson GD Clinical experience with long-term continuation treatment with olanzapine 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York, USA 1996 97055970","DOI":"10.1016\/0924-977X(96)83201-9"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4088\/JCP.v58n0505","article-title":"Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia","volume":"58","author":"Tran","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1192\/bjp.172.6.499","article-title":"Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses","volume":"172","author":"Tran","year":"1998","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0363|cit363","unstructured":"Tran PV Tollefson GD Creanga D Zhang F Wang J Vangala S Clinical experience with olanzapine in patients of African, Asian, and Hispanic descent World Psychiatric Association; Hamburg; Germany 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1192\/bjp.174.1.15","article-title":"Olanzapine versus haloperidol in the treatment of schizoaffective disorder: acute and long-term therapy","volume":"174","author":"Tran","year":"1999","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0365|cit365","unstructured":"Croghan TW Heilman DK Validity of SF36 for severely mentally ill patients 151st Annual Meeting of American Psychiatric Association; May 30-June 4; Toronto; ON, Canada 1998"},{"issue":"7","key":"10.1002\/14651858.CD013425.pub2-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/00005650-199907000-00008","article-title":"Reliability, validity, application of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol","volume":"37","author":"Tunis","year":"1999","journal-title":"Medical Care"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0367|cit367","first-page":"38","article-title":"Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia","volume":"60 Suppl 19","author":"Tunis","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0368|cit368","doi-asserted-by":"crossref","unstructured":"Williamson D Beasley C Tran P Tamura N Sanger T Tollefson G Olanzapine versus haloperidol: results of the multi-center international trial 8th Congress of the Association of European Psychiatrists; Jul 7-12; London; England, UK 1996","DOI":"10.1016\/0924-9338(96)88582-8"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0369|cit369","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0920-9964(97)88829-9","article-title":"A blinded, controlled, long-term study of the comparative incidence of treatement-emergent tardive dyskinesia with olanzapine or haloperidol","volume":"29","author":"Wright","year":"1998","journal-title":"Schizophrenia Research"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0920-9964(97)88829-9","article-title":"A blinded, controlled, long-term study of the comparative incidence of treatment-resistant tardive dyskinesia with olanzapine or haloperidol","volume":"29","author":"Wright","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0371|cit371","doi-asserted-by":"crossref","unstructured":"Zhang F Tohen M Gannon KS Breier A Olanzapine versus haloperidol: assessment of cognitive function in patients with schizoaffective disorder, bipolar type Journal of the European College of Neuropsychopharmacology 1999 S247 21040726","DOI":"10.1016\/S0924-977X(99)80226-0"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.1016\/S0924-977X(99)80225-9","article-title":"Olanzapine versus haloperidol in schizoaffective disorder, bipolar type: a~repeated measures analysis","volume":"9","author":"Zhang","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0373|cit373","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1177\/0976500X2211286","article-title":"Homocysteine levels and clinical outcomes in schizophrenia\u2014a pilot randomized controlled trial","volume":"13","author":"Vedam","year":"2022","journal-title":"Journal of Pharmacology and Pharmacotherapeutics"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0374|cit374","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/JCP.0000000000000050","article-title":"Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine","volume":"34","author":"Walther","year":"2014","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"04","key":"10.1002\/14651858.CD013425.pub2-BIB0375|cit375","first-page":"217","article-title":"Randomized controlled study of haloperidol and olanzapine in the treatment of schizophrenia efficacy and safety [Google Translate]","volume":"-","year":"2012","journal-title":"Chinese Journal of Nervous and Mental Diseases [Zhongguo Shen Jing Jing Shen Ji Bing Za Zhi; \u4e2d\u56fd\u795e\u7ecf\u7cbe\u795e\u75be\u75c5\u6742\u5fd7]"},{"issue":"13","key":"10.1002\/14651858.CD013425.pub2-BIB0376|cit376","first-page":"26","article-title":"Olanzapine and haloperidol controlled study of patients with refractory schizophrenia affect the quality of life of the [Google Translate]","volume":"-","year":"2013","journal-title":"\u4e2d\u56fd\u536b\u751f\u4ea7\u4e1a"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0377|cit377","first-page":"20","article-title":"A double blind comparing study between the effects of haloperidol and olanzapine on the quality of life of the patients with schizophrenia","volume":"27","author":"Zheng","year":"2004","journal-title":"Journal of Jining Medical College"},{"issue":"18","key":"10.1002\/14651858.CD013425.pub2-BIB0378|cit378","first-page":"107","article-title":"\u5965\u6c2e\u5e73\u4e0e\u6c1f\u54cc\u5576\u9187\u5bf9\u7cbe\u795e\u5206\u88c2\u75c7\u60a3\u8005\u751f\u6d3b\u8d28\u91cf\u5f71\u54cd\u7684\u5bf9\u7167\u7814\u7a76","volume":"-","year":"2014","journal-title":"\u4e2d\u5916\u5065\u5eb7\u6587\u6458"},{"issue":"32","key":"10.1002\/14651858.CD013425.pub2-BIB0379|cit379","first-page":"76","article-title":"Changes in the serum levels of prolactin and growth hormone in patients with schizophrenic after different drug administration","volume":"9","author":"Chu","year":"2005","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"issue":"12","key":"10.1002\/14651858.CD013425.pub2-BIB0380|cit380","first-page":"141","article-title":"Olanzapine control study of first episode schizophrenia [Google Translate]","volume":"16","year":"2010","journal-title":"China Contemporary Medicine [\u5f53\u4ee3\u533b\u5b66]"},{"issue":"8","key":"10.1002\/14651858.CD013425.pub2-BIB0381|cit381","first-page":"133","article-title":"Tablets of olanzapine treatment of schizophrenia and the effect of haloperidol compared SBR [Google Translate]","volume":"4","year":"2010","journal-title":"Chinese Journal of Modern Drug Application [\u4e2d\u56fd\u73b0\u4ee3\u836f\u7269\u5e94\u7528]"},{"issue":"16","key":"10.1002\/14651858.CD013425.pub2-BIB0382|cit382","first-page":"47+67","article-title":"Olanzapine and haloperidol in the treatment of schizophrenia comparison of efficacy [Google Translate]","volume":"-","year":"2013","journal-title":"Medical Journal of Chinese People's Health [\u4e2d\u56fd\u6c11\u5eb7\u533b\u5b66]"},{"issue":"21","key":"10.1002\/14651858.CD013425.pub2-BIB0383|cit383","first-page":"11","article-title":"\u6c1f\u54cc\u5576\u9187\u4e0e\u5965\u6c2e\u5e73\u6cbb\u7597\u7cbe\u795e\u5206\u88c2\u75c7\u7684\u4e34\u5e8a\u7597\u6548\u5bf9\u6bd4\u7814\u7a76","volume":"9","year":"2016","journal-title":"\u4e34\u5e8a\u5408\u7406\u7528\u836f\u6742\u5fd7"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0384|cit384","unstructured":"Zheng R Olanzapine treatment of positive symptoms of schizophrenia and ammonia piperidinol control study Acta Academiae Medicinae Suzhou [\u82cf\u5dde\u533b\u5b66\u9662\u5b66\u62a5] 2003 23 2 218 9"},{"issue":"10","key":"10.1002\/14651858.CD013425.pub2-BIB0385|cit385","first-page":"1451","article-title":"\u5965\u6c2e\u5e73\u5bf9\u7cbe\u795e\u5206\u88c2\u75c7\u60a3\u8005\u8ba4\u77e5\u529f\u80fd\u548c\u751f\u6d3b\u8d28\u91cf\u6539\u5584\u4f5c\u7528\u53ca\u7597\u6548","volume":"22","year":"2014","journal-title":"China Journal of Health Psychology [\u4e2d\u56fd\u5065\u5eb7\u5fc3\u7406\u5b66\u6742\u5fd7]"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0386|cit386","first-page":"24","article-title":"Comparison of effectiveness of antipsychotics in schizophrenia: second-generation versus the first-generation","volume":"32","author":"Zubair","year":"2020","journal-title":"Journal of Ayub Medical College Abbottabad"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0387|cit387","unstructured":"Addington DE Addington JM Costs of novel antipsychotics in clinical practice 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998 1998"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0388|cit388","first-page":"71","article-title":"The relationship between negative symptoms of schizophrenia with extrapyramidal side effects with haloperidol and olanzapine","volume":"34","author":"Allan","year":"1998","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0389|cit389","doi-asserted-by":"crossref","unstructured":"Allison DB Mentor JL Heo M Weiden PJ Chandler LP Cappelleri J Weight gain associated with conventional and newer antipsychotics: a meta-analysis 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998 1998","DOI":"10.1016\/S0924-9338(99)80606-3"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0390|cit390","unstructured":"Allison DB Mentor JL Heo M Weiden PJ Chandler LP Cappelleri J Weight gain associated with conventional and newer antipsychotics: a meta-analysis Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum. Glasgow, Scotland, UK; July 12-16, 1998 1998"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0391|cit391","first-page":"518","article-title":"Early intervention in antipsychotic-induced weight gain in first episode psychosis","volume":"31","author":"Alvarez","year":"2005","journal-title":"International Congress on Schizophrenia Research"},{"issue":"8","key":"10.1002\/14651858.CD013425.pub2-BIB0392|cit392","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.4088\/jcp.v67n0812","article-title":"Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial.","volume":"67","author":"Alvarez-Jimenez","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0393|cit393","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.schres.2009.10.012","article-title":"Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial","volume":"116","author":"\u00c1lvarez-Jim\u00e9nez","year":"2010","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0394|cit394","unstructured":"Apicella A National Alliance for Research on Schizophrenia and Depression www.mhsource.com\/narsad\/bd\/studyops.html 2001"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0395|cit395","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1017\/S1461145703003742","article-title":"Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine","volume":"6","author":"Apiquian","year":"2003","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0396|cit396","unstructured":"Aquila R Weiden PJ Kinon BJ Milton DR Zygmunt A Swindle RW Effectiveness of olanzapine upon psychiatric and vocational rehabilitation outcomes 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA 2000"},{"issue":"11","key":"10.1002\/14651858.CD013425.pub2-BIB0397|cit397","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1176\/appi.ajp.160.11.2066","article-title":"Olanzapine effects on auditory sensory gating in schizophrenia","volume":"160","author":"Arango","year":"2003","journal-title":"American Journal of Psychiatry"},{"issue":"1-2 Suppl","key":"10.1002\/14651858.CD013425.pub2-BIB0398|cit398","first-page":"197","article-title":"Lack of P50 changes in a randomized double blind study of olanzapine and haloperidol","volume":"49","author":"Arango","year":"2001","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0399|cit399","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1016\/S0924-977X(16)31276-7","article-title":"Effects of atypical and conventional antipsychotics on cognition in schizophrenia","volume":"2(26)","author":"Arous","year":"2016","journal-title":"European Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013425.pub2-BIB0400|cit400","first-page":"102s","article-title":"Patient attitude after switch to ziprasidone from other antipsychotics","volume":"17","author":"Awad","year":"2002","journal-title":"European Psychiatry (11th Association of European Psychiatrists Congress, 2002 4-8th May, Stockholm, Sweden)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0920-9964(03)80427-9","article-title":"Effectiveness of rapid initial dose escalation of oral olanzapine for acute agitation","volume":"60","author":"Baker","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0402|cit402","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.jcp.0000085406.08426.a8","article-title":"Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation","volume":"23","author":"Baker","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0403|cit403","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1590\/S1516-44462011000100008","article-title":"Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone","volume":"33","author":"Balda\u00e7ara","year":"2011","journal-title":"Brazilian Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0404|cit404","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00004850-200511000-00006","article-title":"Assessing cardiovascular risks of olanzapine treatment: a 6-month study versus haloperidol in schizophrenia patients","volume":"20","author":"Barak","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0405|cit405","doi-asserted-by":"crossref","first-page":"S474","DOI":"10.1016\/S0924-977X(05)80980-0","article-title":"A multi-centered study evaluating the effects of haloperidol and olanzapine on depressive symptoms in schizophrenic patients.","volume":"15","author":"Bayar","year":"2005","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0406|cit406","unstructured":"Beasley C Tollefson G Wood G Tran P Satterlee W Beuzen J Safety overview of olanzapine Xth World Congress of Psychiatry. Madrid, Spain; August 23-28, 1996 1996"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0920-9964(00)90783-7","article-title":"Relapse prevention with olanzapine","volume":"41","author":"Beasley","year":"2000","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0408|cit408","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.jcp.0000095348.32154.ec","article-title":"A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse","volume":"23","author":"Beasley","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013425.pub2-BIB0409|cit409","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1016\/S0924-977X(00)80345-4","article-title":"Relapse prevention with olanzapine","volume":"10","author":"Beasley Jr","year":"2000","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0410|cit410","unstructured":"Beuzen JN Olanzapine - cognitive and motor effects in healthy elderly Xth World Congress of Psychiatry. Madrid, Spain; August 23-28, 1996 1996"},{"issue":"2-3","key":"10.1002\/14651858.CD013425.pub2-BIB0411|cit411","doi-asserted-by":"crossref","first-page":"VC2","DOI":"10.1016\/0920-9964(96)85439-9","article-title":"The effect of olanzapine on cognition and psychomotor function in healthy elderly volunteers","volume":"18","author":"Taylor","year":"1996","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0412|cit412","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/026988119500900212","article-title":"State of the Art - Winter Workshop on Schizophrenia, Les Diablerets, Switzerland, January 1994","volume":"9","author":"Birkett","year":"1995","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0413|cit413","first-page":"419","article-title":"Efficacy and metabolic profile of bifeprunox in patients with schizophrenia","volume":"33","author":"Barbato","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0414|cit414","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.schres.2007.12.371","article-title":"304\u2013Efficacy of bifeprunox in patients in the post-acute, maintenance phase of schizophrenia: Findings from a 6-month study","volume":"98","author":"Bourin","year":"2008","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0415|cit415","doi-asserted-by":"crossref","first-page":"S454","DOI":"10.1016\/S0924-977X(07)70689-2","article-title":"Long-term efficacy and safety of bifeprunox in stable patients with schizophrenia: findings from a 6-month study","volume":"17","author":"Bourin","year":"2007","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0416|cit416","first-page":"422","article-title":"Bifeprunox is safe and effective in preventing deterioration in patients with stable schizophrenia: results from a 6-month, placebo-controlled study","volume":"33","author":"Ostergard","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0417|cit417","first-page":"459","article-title":"Metabolic effects of bifeprunox in patients with schizophrenia","volume":"33","author":"Shapira","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0418|cit418","unstructured":"Britto D Ziprasidone quality of life study in the treatment of chronic schizophrenia National Research Register 2002 1"},{"issue":"1-3","key":"10.1002\/14651858.CD013425.pub2-BIB0419|cit419","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.schres.2007.04.027","article-title":"FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol","volume":"94","author":"Buchsbaum","year":"2007","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0420|cit420","first-page":"S426","article-title":"White matter volume and anisotropy in never medicated psychotic adolescents treated with olanzapine and haloperidol","volume":"17","author":"Buchsbaum","year":"2004","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0421|cit421","first-page":"148","article-title":"Antipsychotic response prediction with FDG-PET in schizophrenia","volume":"3:S1","author":"Buchsbaum","year":"2004","journal-title":"World Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0422|cit422","unstructured":"Burgoyne K Ananth J Gadasally R Smith M Maintenance treatment with olanzapine for schizophrenic patients Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum. Glasgow, Scotland, UK; July 12-16, 1998 1998"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0423|cit423","doi-asserted-by":"crossref","unstructured":"Burgoyne K Ananth J Smith M Swartz JR Gadasally R Arns P Olanzapine versus haloperidol: the results of a double-blind study on acute psychotic patients XXth Collegium Internationale Neuro-psychopharmacologicum. Melbourne, Australia; June 23-27, 1996 1996","DOI":"10.1016\/0924-977X(96)87986-7"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0424|cit424","unstructured":"Castilla R Early medication intervention in the treatment of psychosis in children International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada) 2002 S51"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0425|cit425","first-page":"139","article-title":"Longterm efficacy and safety of atypical antipsychotics and haloperidol in neuroleptic naive psychotic patients","volume":"11","author":"Chetvertnykh","year":"2008","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0426|cit426","unstructured":"Clouth J Pharmacoeconomic evaluation of the treatment of schizophrenia in Germany: a comparison of olanzapine and haloperidol APA Annual Meeting, May 15-20, 1999, Washington, DC 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0427|cit427","unstructured":"Corya S Dub\u00e9 S Andersen SW Sanger TM Clemow D Tohen M Olanzapine-fluoxetine combination for psychotic major depression International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada) 2002 S144"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0428|cit428","first-page":"160","article-title":"Effects of oral ziprasidone on weight and serum lipids in patients with schizophrenia","volume":"3 Suppl 1","author":"Cutler","year":"2002","journal-title":"Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0429|cit429","unstructured":"Dalheim LJ Weiden PJ Aquila R Standard J Emanuel M Zygmunt A Olanzapine crossover in stable outpatients American Psychiatric Association, 150th Annual Meeting, San Diego, CA, USA 1997"},{"issue":"60","key":"10.1002\/14651858.CD013425.pub2-BIB0430|cit430","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0920-9964(03)81269-0","article-title":"The effects of antipsychotics on cortical inhibition using transcranial magnetic stimulation","volume":"1","author":"Daskalakis","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0431|cit431","unstructured":"Davis JM Janicak PG Sharma RP Manav R Comparisons of the effects of the newer atypical antipsychotics in the treatment of schizophrenia: a meta-analysis 151st Annual Meeting of American Psychiatric Association. May 30-June 4, Toronto, ON, Canada 1998"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0432|cit432","unstructured":"Davis JM Sharma RP Manav R Comparisons of the effects of the newer atypical antipsychotics in the treatment of schizophrenia: a meta-analysis 151st Annual Meeting of American Psychiatric Association. May 30-June 4, Toronto, ON, Canada 1998"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0433|cit433","unstructured":"Devanand DP Michaels K Sackeim HA Marder K Mayeux RP Antipsychotics in the treatment of dementia complicated by psychosis 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0434|cit434","unstructured":"Devanand DP Classic neuroleptics in dementia 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998 1998"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0435|cit435","unstructured":"Docherty JP Napolitano J Mahmoud RA Martinez RA Lasser RA Pandina GJ Anticholinergic effect of atypical antipsychotics in elderly patients 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA 2002"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013425.pub2-BIB0436|cit436","first-page":"S314","article-title":"Anticholinergic effect of atypical antipsychotics in elderly patients","volume":"12","author":"Tune","year":"2002","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0437|cit437","unstructured":"Dolnak DR Hyman Rapaport M Caligiuri M Lohr J Golshan S A prospective, randomized, double-blind study contrasting motor dysfunction, negative symptoms and functioning in schizophrenic patients treated with olanzapine and risperidone. 40th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU); 2000 May 30 - Jun 2; Boca Raton, Florida, USA 2000 133"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0438|cit438","unstructured":"Dolnak DR Minn K Wieneke M Espinoza S Olanzapine versus haloperidol in the treatment of schizophrenia American Psychiatric Association, 149th Annual Meeting; May 4-9, 1996 1996"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0439|cit439","unstructured":"Dolnak DR Rapaport MH Michael C Shahrokh G Motor dysfunction in schizophrenia 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA 2000"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0440|cit440","unstructured":"Dolnak DR Rapaport MH Michael C Shahrokh G Motor dysfunction in schizophrenia 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA 2002"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0441|cit441","unstructured":"Dolnak R Rapaport MH A prospective, randomized, doubleblind study examining functioning in schizophrenic patients treated with olanzapine and risperidone Schizophrenia Research (8th International Congress on Schizophrenia Research; 2001 Apr 28 - May 2; British Columbia, Canada) 2001 225 6 21040726"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0442|cit442","doi-asserted-by":"crossref","unstructured":"Dossenbach M Friedel P Folnegovic V Jackovljevic M Hutujac L Uglesic B Olanzapine vs. fluphenazine - 6 weeks treatment of acute schizophrenia 10th European Colleague of Neuropsychopharmacology Congress 1997 September 13-17 Vienna 1997","DOI":"10.1016\/S0924-977X(97)88729-9"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0443|cit443","first-page":"125","article-title":"Impact of atypical and conventional antipsychotics on the quality of life of patients with schizophrenia: a preliminary report from Lagos teaching hospitals","volume":"-","author":"Erinfolami","year":"2009","journal-title":"unknown source"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0444|cit444","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0306-4530(01)00016-6","article-title":"Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients","volume":"26","author":"Esel","year":"2001","journal-title":"Psychoneuroendocrinology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0445|cit445","first-page":"0","article-title":"Evaluation of therapeutic efficacy of treatment with olanzapine and halopridol on regional cerebral blood flow measured by SPECT in patients with schizophrenia, correlating with the response to treatment","volume":"NA","author":"Fallahi","year":"2011","journal-title":"Study protocol"},{"issue":"8","key":"10.1002\/14651858.CD013425.pub2-BIB0446|cit446","first-page":"445","article-title":"Changing neuroleptics: from new to conventional - and vice versa","volume":"29","author":"Finzen","year":"2002","journal-title":"Psychiatrische Praxis"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0447|cit447","unstructured":"Fleming K Potkin SG Alva G Carreon D Dissociation of improvement in neurocognition and negative symptomatology with olanzapine and clozapine conference abstract Schizophrenia Research (Abstracts of The 7th International Congress on Schizophrenia Research; 1999 Apr 17-21; Santa Fe, USA) 1999 279"},{"issue":"8","key":"10.1002\/14651858.CD013425.pub2-BIB0448|cit448","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1592\/phco.29.8.930","article-title":"Intramuscular haloperidol versus intramuscular olanzapine for treatment of acute agitation: a cost-minimization study","volume":"29","author":"Freeman","year":"2009","journal-title":"Pharmacotherapy: the Journal of Human Pharmacology and Drug Therapy"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0449|cit449","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s002130100835","article-title":"P300 and symptom improvement in schizophrenia","volume":"158","author":"Gallinat","year":"2001","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0450|cit450","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/01.jcp.0000145337.07676.2f","article-title":"Absence of effect of olanzapine on primary polydipsia: results of a double-blind, randomized study","volume":"24","author":"Goldman","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0451|cit451","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00702-002-0803-7","article-title":"Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia","volume":"110","author":"Gothelf","year":"2003","journal-title":"Journal of Neural Transmission"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0452|cit452","article-title":"Clinical effectiveness of atypical vs typical antipsychotics in treatment of schizophrenic patients","volume":"-","author":"Gabos Grecu","year":"2006","journal-title":"unknown"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0453|cit453","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/01.jcp.0000170032.78060.cd","article-title":"Regular-dose risperidone on QTc intervals","volume":"25","author":"Chiu","year":"2005","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0454|cit454","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition","volume":"24","author":"Harrigan","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0455|cit455","article-title":"Predicting best treatment response in schizophrenia with striatal function","volume":"-","author":"Hazlett","year":"2009","journal-title":"NA"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0456|cit456","article-title":"Prediction of antipsychotic response with diffusion tensor imaging","volume":"-","author":"Haznedar","journal-title":"unknown"},{"issue":"7","key":"10.1002\/14651858.CD013425.pub2-BIB0457|cit457","first-page":"343","article-title":"Czech results of the RODOS study: comparison of risperidone and olanzapine from the point of view of efficacy, tolerability and treatment costs","volume":"97","author":"Hrdlicka","year":"2001","journal-title":"Ceska A Slovenska Psychiatrie"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0458|cit458","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/JCP.0b013e3181db8715","article-title":"Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan","volume":"30","author":"Hsu","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0459|cit459","doi-asserted-by":"crossref","unstructured":"Irwin J Moses SN Edgar JC Torres F Thoma RJ Hanlon FM Olanzapine and risperidone in schizophrenia: a randomized double-blind crossover study Schizophrenia Research 2003 286","DOI":"10.1016\/S0920-9964(03)80469-3"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0460|cit460","first-page":"232","article-title":"Haloperidol versus olanzapine induced weight gain and clinical relevance, a double-blind and open label comparison","volume":"1-2 Suppl","author":"Jarboe","year":"2001","journal-title":"Schizophrenia Research (8th International Congress on Schizophrenia Research; 2001 Apr 28 - May 2; British Columbia, Canada)"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0461|cit461","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1017\/S1461145701002590","article-title":"Adjunctive high-dose glycine in the treatment of schizophrenia","volume":"4","author":"Javitt","year":"2001","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0462|cit462","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/oxfordjournals.schbul.a006967","article-title":"Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications","volume":"28","author":"Jerrell","year":"2002","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0463|cit463","unstructured":"Kalali A Lasser R Campbell B Cucchiaro J El-Bizri H Guven A The management of cultural differences and the importance of safety monitoring in global studies: the realize clinical program 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico 2000"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0464|cit464","first-page":"S51","article-title":"A comparative study of efficacy and safety of olanzapine versus haloperidol in schizophrenia in a tertiary care hospital.","volume":"54","year":"2012","journal-title":"Indian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0465|cit465","doi-asserted-by":"crossref","unstructured":"Kinon BJ Basson B Wang J Malcolm SK Stauffer VL Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone 40th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU); 2000 May 30 - Jun 2; Boca Raton, Florida 2000","DOI":"10.1016\/S0924-977X(00)80349-1"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0466|cit466","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0920-9964(00)90778-3","article-title":"Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone","volume":"41","author":"Kinon","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0467|cit467","doi-asserted-by":"crossref","unstructured":"Kinon BJ Basson BR Malcolm SK Breier A Strategies for switching from conventional antipsychotic drugs and risperidone to olanzapine World Congress of Psychiatry (WPA). Hamburg, Germany; August 8-11, 1999 1999","DOI":"10.4088\/JCP.v61n1105"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0468|cit468","doi-asserted-by":"crossref","unstructured":"Kinon BJ Basson BR Malcolm SK Tollefson GD Strategies for switching from conventional antipsychotic drugs and risperidone to olanzapine 2nd Annual Meeting of the College of Psychiatric and Neurologic Pharmacists. Lake Tahoe, NV, USA; March 25-28, 1999 1999","DOI":"10.1016\/S0306-4530(00)90181-1"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0469|cit469","unstructured":"Kinon BJ Basson BR Malcolm SK Tollefson GD Strategies for switching from conventional antipsychotic drugs and risperidone to olanzapine American College of Neuropsychopharmacology (ACNP). Las Carabas, Puerto Rico; December 14-18, 1998 1998"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0470|cit470","unstructured":"Kinon BJ Basson BR Malcolm SK Tollefson GD Strategies for switching from conventional antipsychotic drugs and risperidone to olanzapine American Psychiatric Association (APA). Washington, DC, USA; May 15-20, 1999 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0471|cit471","unstructured":"Kinon BJ Basson BR Malcolm SK Tollefson GD Strategies for switching from conventional antipsychotic drugs and risperidone to olanzapine Biennial Meeting, International Congress on Schizophrenia Research (ICSR). Santa Fe, NM, USA; April 17-21, 1999 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0472|cit472","unstructured":"Kinon BJ Basson BR Wang J Malcolm SK Stauffer VL Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone International Society of Psychoneuroendocrinology (ISPNE). Orlando, FL, 1999; July 30-August 3, 1999 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0473|cit473","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0920-9964(03)80366-3","article-title":"Olanzapine reduces neuroleptic-induced hyperprolactinemia in schizophrenia","volume":"60","author":"Ahl","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0474|cit474","unstructured":"Kinon BJ Liu H Ahl J Baker RW Longitudinal effects of olanzapine on fasting serum lipids: a randomized, prospective, four- month study 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA 2003"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0475|cit475","unstructured":"Kinon BJ Liu H Ahl J Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA 2003"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0476|cit476","first-page":"A60","article-title":"Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine","volume":"14","author":"Kinon","year":"2000","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0477|cit477","unstructured":"Knegtering R Boks M Wiersma D Blijd C Bruggeman R Oer RBV Sexual dysfunctions in patients on antipsychotics 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA 2002"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0478|cit478","unstructured":"Knegtering R Boks M Wiersma D Blijd C Bruggeman R van Oer RB Sexual dysfunctions in patients on antipsychotics 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA 2000"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0479|cit479","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/01.jcp.0000106220.36344.04","article-title":"A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning","volume":"24","author":"Knegtering","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0480|cit480","first-page":"S59","article-title":"Differential effects of antipsychotic drugs on clinical symptoms and cognitive functions in the treatment of schizophrenia","volume":"Suppl 2","author":"Kolff","year":"2000","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0481|cit481","first-page":"S525","article-title":"Comparison of the effects of intramuscular antipsychotics injection in the treatment of acute agitation in psychosis","volume":"-","author":"Kong","journal-title":"unknown"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0482|cit482","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1176\/appi.ajp.2020.20010052","article-title":"The importance of conduct disorder in the treatment of violence in schizophrenia: efficacy of clozapine compared with olanzapine and haloperidol","volume":"178","author":"Krakowski","year":"2021","journal-title":"American Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD013425.pub2-BIB0483|cit483","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0924-9338(02)00692-2","article-title":"Olanzapine and improvement of tardive dyskinesia","volume":"17","author":"Kucerova","year":"2002","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0484|cit484","unstructured":"Lahti AC Holcomb HH Weiler MA Parwani A Michaelidis T Medoff DR Changes rcbf after acute challenge with haloperidol and olanzapine in patients with schizophrenia Schizophrenia Research (Abstracts of The 7th International Congress on Schizophrenia Research; 1999 Apr 17-21; Santa Fe, USA) 1999 224 20137242"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0485|cit485","doi-asserted-by":"crossref","DOI":"10.1016\/S0920-9964(03)81204-5","article-title":"Time course of RCBF changes with haloperidol and olanzapine over a six week treatment","volume":"-","author":"Lahti","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0486|cit486","unstructured":"Open-label clinical trial on antipsychotic efficacy and safety of olanzapine in schizophrenic patients with positive or negative symptomatology Data supplied to the Cochrane Schizophrenia Group 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0487|cit487","unstructured":"Efficacy and safety of olanzapine in the treatment of schizophrenic, schizophreniform and schizoaffective patients in Saudi Arabia Data supplied to the Cochrane Schizophrenia Group 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0488|cit488","unstructured":"Olanzapine in schizophrenic patients intolerant of, or resistant to, clozapine Data supplied to the Cochrane Schizophrenia Group 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0489|cit489","unstructured":"Safety and efficacy of olanzapine in patients with severe haloperidol side effects in Romania Data supplied to the Cochrane Schizophrenia Group 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0490|cit490","unstructured":"Efficacy and safety of olanzapine in the treatment of schizophrenic and schizoaffective patients in Russia Data supplied to the Cochrane Schizophrenia Group 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0491|cit491","unstructured":"Open-label olanzapine Data supplied to the Cochrane Schizophrenia Group 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0492|cit492","unstructured":"Efficacy and safety of olanzapine in the treatment of schizophrenic patients in China Data supplied to the Cochrane Schizophrenia Group 1999"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0493|cit493","first-page":"182","article-title":"Calming versus sedative effects of IM olanzapine in agitated patients","volume":"53","author":"Battaglia","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"10","key":"10.1002\/14651858.CD013425.pub2-BIB0494|cit494","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.clinthera.2005.10.001","article-title":"A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia","volume":"27","author":"Battaglia","year":"2005","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0495|cit495","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0735-6757(02)42249-8","article-title":"Calming versus sedative effects of intramuscular olanzapine in agitated patients","volume":"21","author":"Battaglia","year":"2003","journal-title":"American Journal of Emergency Medicine"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0496|cit496","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0924-9338(02)80471-0","article-title":"Calming versus sedative effects of IM olanzapine in agitated patients","volume":"17","author":"David","year":"2002","journal-title":"European Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD013425.pub2-BIB0497|cit497","first-page":"78S","article-title":"QTc intervals during treatment with IM olanzapine in acutely agitated patients","volume":"51","author":"David","year":"2002","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0498|cit498","article-title":"A double-blind randomised comparison of the efficacy and safety of short acting intramuscular olanzapine, short acting intramuscular haloperidol and intramuscular placebo inpatients with schizophrenia","volume":"-","author":"George","year":"2000","journal-title":"unknown source"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0499|cit499","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1176\/appi.ajp.162.5.939","article-title":"Evidence for onset of antipsychotic effects within the first 24 hours of treatment","volume":"162","author":"Kapur","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0500|cit500","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0165-1781(03)00107-0","article-title":"Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients","volume":"119","author":"Lindborg","year":"2003","journal-title":"Psychiatry Research"},{"issue":"11","key":"10.1002\/14651858.CD013425.pub2-BIB0501|cit501","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1177\/070674370304801102","article-title":"Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.","volume":"48","author":"Wright","year":"2003","journal-title":"Canadian Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0502|cit502","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/S0149-2918(03)80129-7","article-title":"A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy","volume":"25","author":"Wright","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0503|cit503","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archpsyc.59.5.441","article-title":"A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia","volume":"59","author":"Breier","year":"2002","journal-title":"Archives of General Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD013425.pub2-BIB0504|cit504","first-page":"21S","article-title":"A double-blind dose response study comparing intramuscular (IM) olanzapine, haloperidol, and placebo in acutely agitated schizophrenic patients","volume":"49","author":"Breier","year":"2001","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0505|cit505","first-page":"77","article-title":"Intramuscular olanzapine: dose-related improvement in acutely agitated patients with schizophrenia","volume":"5","author":"Breier","year":"2001","journal-title":"Proceedings of the 154th Annual Meeting of the American Psychiatric Association"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0506|cit506","article-title":"10 mg intramuscular olanzapine reduces acute agitation in schizophrenia more effectively than lower doses","volume":"6","author":"Smith","year":"2003","journal-title":"Evidence-Based Mental Health"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0507|cit507","first-page":"250","article-title":"A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients","volume":"49","author":"Wright","year":"2001","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0508|cit508","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/JCP.0000000000000120","article-title":"A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior","volume":"34","author":"Chan","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0509|cit509","first-page":"1","article-title":"Clinical Study Summary: F1D-TW-S025","volume":"NA","year":"2006","journal-title":"Unpublished data"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0510|cit510","unstructured":"Lima MS Mari JJ Costa AMN Alexandrini N Filho SR Oliverira IR Quality of life of patients with schizophrenia: a randomised, naturalistic, controlled trial comparing olanzapine with typical antipsychotics in Brazil Eli Lilly and Company"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0511|cit511","unstructured":"Lima MS de Jesus Mari J Costa AMN Alexandrini N Filho SR de Oliveira IR Quality of life of patients with schizophrenia: a randomized, naturalistic, controlled trial comparing olanzapine with typical antipsychotics in Brazil 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA 2003"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0512|cit512","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0920-9964(03)80494-2","article-title":"A nine month naturalistic randomized controlled trial comparing olanzapine and conventional antipsychotics for schizophrenia and related disorders","volume":"60","author":"Mari","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0513|cit513","unstructured":"Lima MS Costa AMN Alexandrini N Filho SR de Oliveira IR Olanzapine versus conventional antipsychotics: long-term risk of tardive dyskinesia 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA 2003"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0514|cit514","unstructured":"Lindenmayer JP Beyond symptoms: optimizing real-world outcomes 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998 1998"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0515|cit515","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00004714-200106000-00022","article-title":"Hyperglycemia in patients with schizophrenia who are treated with olanzapine","volume":"21","author":"Lindenmayer","year":"2001","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0516|cit516","doi-asserted-by":"crossref","unstructured":"Loza B Kucharska-Pietura K Debowska G Atypical versus typical antipsychotic treatment prognosis in first-episode paranoid schizophrenia based on wcst and dichotic listening scores European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13-17; Istanbul, Turkey) 2001 285","DOI":"10.1016\/S0924-977X(01)80372-2"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0517|cit517","doi-asserted-by":"crossref","first-page":"S298","DOI":"10.1016\/S0924-977X(02)80431-X","article-title":"Atypical antipsychotic treatment prognosis in first-episode paranoid schizophrenia based on syllabic and language-related dichotic listening scores","volume":"Suppl 3","author":"Loza","year":"2002","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0518|cit518","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41398-022-01825-0","article-title":"ATAD3B and SKIL polymorphisms associated with antipsychotic-induced QTc interval change in patients with schizophrenia: a genome-wide association study","volume":"12","author":"Lu","year":"2022","journal-title":"Translational Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0519|cit519","unstructured":"Mahmoud RA Engelhart LM Janagap C Awad G Assessment of symptoms affecting quality of life and patient satisfaction with antipsychotic drugs:new insights for a trial of risperidone\/olanzapine APA Annual Meeting, May 15-20, 1999, Washington, DC 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0520|cit520","unstructured":"Mahmoud RA Engelhart LM Janagap C Dogherty J Symptoms commonly attributed to prolactin:a new assessment tool and findings from a trial of risperidone versus olanzapine APA Annual Meeting, May 15-20, 1999, Washington, DC 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0521|cit521","unstructured":"Marder SR Newer antipsychotics: side-effect profiles 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0522|cit522","first-page":"180","article-title":"Olanzapine versus haloperidol: a randomized, double-blind cross over study with P-31-nuclear magnetic resonance spectroscopy (MRS) and regional cerebral blood flow measurements (fMRI) of the dorsolateral prefrontal cortex (DLPFC) in schizophrenics","volume":"53","author":"Czekalla","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0523|cit523","first-page":"209","article-title":"Reduction of arachidonic acid levels by haloperidol treatment in patients with schizophrenia","volume":"53","author":"Maurer","year":"2002","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0524|cit524","first-page":"S119","article-title":"Olanzapine and quetiapine in the treatment of acute schizophrenia: a descriptive analysis","volume":"Suppl 1","author":"Mauri","year":"2002","journal-title":"International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada)"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0525|cit525","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1192\/bjp.bp.105.019307","article-title":"Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia","volume":"189","author":"McCue","year":"2006","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0526|cit526","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/ebmh.10.3.76","article-title":"Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia","volume":"10","author":"Taylor","year":"2007","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0527|cit527","unstructured":"McElroy SL Atypical antipsychotics in women with bipolar and other psychiatric disorders 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998 1998"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0528|cit528","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0920-9964(97)88712-9","article-title":"The affects of atypical antipsychotic drugs on cognitive functioning in schizophrenia","volume":"29","author":"McGurk","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0529|cit529","unstructured":"McGurk SR The effects of atypical antipsychotic drugs on cognitive function in schizophrenia 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998 1998"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0530|cit530","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0006-3223(02)01790-0","article-title":"Atypical antipsychotic drugs improve cognition in schizophrenia","volume":"51","author":"Meltzer","year":"2003","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0531|cit531","unstructured":"Mintzer JE Efficacy and safety of atypical neuroleptics in dementia 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998 1998"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0532|cit532","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1016\/S0924-977X(03)92034-7","article-title":"A preliminary study of the pharmacokinetics and tolerability of higher dose oral olanzapine (20, 30, or 40mg\/day) in stable patients with serious mental disorders","volume":"13","author":"Mitchell","year":"2003","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0533|cit533","unstructured":"Mosolov SN Biological treatment of mental disorders in Russia 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998 1998"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0534|cit534","unstructured":"Mulqueen AW Wudarsky M Nicolson RJ Gochman P Hamburger S Lenane M Weight gain in pediatric patients on typical and atypical antipsychotics 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA 2000"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0535|cit535","unstructured":"Mulqueen AW Wudarsky M Nicolson RJ Gochman P Hamburger S Lenane M Weight gain in pediatric patients on typical and atypical antipsychotics 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA 2002"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0536|cit536","unstructured":"Naber D Evidence of efficacy of neuroleptics in effective versus negative symptoms 10th European College of Neuropsychopharmacology Congress. Vienna, Austria; September 13-17, 1997 1997"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0537|cit537","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00004714-200302000-00018","article-title":"Efficacy of clozapine in the treatment of atypical antipsychotic refractory schizophrenia: A pilot study","volume":"23","author":"Narendran","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0538|cit538","first-page":"1","article-title":"Modulation of regional brain activation in schizophrenic patients by pharmacological therapy","volume":"NA","author":"Schl\u00f6ss","year":"2007","journal-title":"Study protocol"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0539|cit539","unstructured":"Oliemeulen EAP Jogems-Kosterman BJM van Hoof JJM Is olanzapine a substitute for clozapine? Schizophrenia Research (Abstracts of The 7th International Congress on Schizophrenia Research; 1999 Apr 17-21; Santa Fe, USA) 1999 146 7 20137242"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0540|cit540","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0920-9964(00)90755-2","article-title":"Is olanzapine a substitute for clozapine? The effects on psychomotor performance","volume":"41","author":"Oliemeulen","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0541|cit541","doi-asserted-by":"crossref","unstructured":"Nicolini H Cruz C Camarena B Ortega H 5HT2A and DRD4 molecular genotypes in a clinical trial of olanzapine versus risperidone in schizophrenic patients European College of Neuropsychopharmacology, congress, Vienna, Austria, September 13-17 1997","DOI":"10.1016\/S0924-977X(97)88682-8"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0542|cit542","unstructured":"Ortega-Solo HA Apiquian R Ullca RE Loyzaga C Mendiazabal A Brunner E Olanzapine versus risperidone a double blind trial in Mexican patients Regional meeting of the Collegium Internationale Neuro-Psychopharmacologicum and the Collegio Mexicano de Neuropsicofarmacologia. Acapulco, Mexico; August 21-23, 1997 1997"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0543|cit543","unstructured":"A twelve month, prospective, randomized, active controlled, open label, flexible dose study of paliperidone palmitate compared with oral antipsychotic treatment in adults with schizophrenia who have been recently discharged from an inpatient psychiatric hospital Study protocol 2010"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0544|cit544","first-page":"117","article-title":"Comparaison between olanzapine and haloperidol on the procedural learning and on the striatal D2 receptor occupancy in schizophrenia","volume":"49","author":"Paquet","year":"2001","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0545|cit545","unstructured":"Parellada E Lomena F Catafau A Font M Gomez JC Salamero M Bernardo M Olanzapine versus haloperidol d2 occupancy:a single photon emission tomography study APA Annual Meeting, May 15-20, 1999, Washington, DC 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0546|cit546","unstructured":"Patel R Griffiths K Martinez-Gutierrez A Garcia-Marin L Antipsychotic treatment patterns in patients with schizophrenia: A real-world data analysis of electronic health records Journal of Managed Care: Specialty Pharmacy Supplement Poster Abstracts 2022 28 10-a 54 5"},{"issue":"60","key":"10.1002\/14651858.CD013425.pub2-BIB0547|cit547","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0920-9964(03)80508-X","article-title":"Efficacy and safety of olanzapine, risperidone and haloperidol in acute treatment of patients with first episode psychosis","volume":"1","author":"Perez","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0548|cit548","unstructured":"Lambert M Moritz S Karow A Krausz M Naber D Quality of life in the treatment of schizophrenia- a randomised, open label comparison trial of amisulpride, olanzapine, quetiapine, risperidone and zotepine Schizophrenia Research (Abstract of the 11th Biannual Winter Workshop on Schizophrenia) 2002"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0549|cit549","first-page":"62","article-title":"Depressive symptoms under atypical neuroleptic treatment in schizophrenia","volume":"Suppl 404","year":"2000","journal-title":"Acta Psychiatrica Scandinavica (Abstracts of 13th International Symposium for the Psychological Treatment of Schizophrenia and Other Psychoses (ISPS); 2000 Jun 5-9; Stavanger, Norway)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0550|cit550","first-page":"201","article-title":"A comparison of clinical outcome of four atypical neuroleptics in the treatment of schizophrenia","volume":"5","author":"Perro","year":"1999","journal-title":"Pharmacopsychiatry (Abstracts of 21st Symposium of the Arbeitsgemeinschaft Neuropsychopharmakologie Und Pharmakopsychiatrie (AGNP); 1999 Oct 6-9; Nuremberg, Germany)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0551|cit551","doi-asserted-by":"crossref","unstructured":"Perro C Naber D Lambert M Moritz S Krause M A prospective clinical comparative-study of four atypical antipsychotic agents in the treatment of schizophrenia 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany 1999 13","DOI":"10.2165\/00128413-199912110-00012"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0552|cit552","first-page":"S184","article-title":"The effects of olanzapine or fluphenazine on peripheral biochemical markers in schizophrenic patients","volume":"Suppl 1","author":"Pivac","year":"2002","journal-title":"International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0553|cit553","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.psychres.2016.04.097","article-title":"The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis: Haloperidol versus olanzapine","volume":"241","author":"Rasmussen","year":"2016","journal-title":"Psychiatry Research"},{"issue":"1,2","key":"10.1002\/14651858.CD013425.pub2-BIB0554|cit554","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0920-9964(97)88681-1","article-title":"Efficacy of a 12 week trial of olanzapine in treatment refractory schizophrenia or schizoaffective disorder","volume":"29","author":"Ratakonda","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0555|cit555","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0140-6736(05)63186-8","article-title":"Olanzapine","volume":"350","author":"Kerwin","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0556|cit556","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0140-6736(97)22018-0","article-title":"Olanzapine: a novel atypical neuroleptic agent","volume":"349","author":"Reus","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0557|cit557","unstructured":"Rosebush P Mazurek M Olanzapine versus haloperidol in randomized trials of the first-episode patients with schizophrenia Stanley Foundation Research Awards - 2000 ResearchAward Recipients (http:\/\/www.stanleyresearch.org\/)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0558|cit558","unstructured":"Sacchetti E Valsecchi P Regini C Galluzzo A Cacciani P Agrimi E Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study 16th European College of Neuropsychopharmacology (ECNP), 2003 Sep 20-24, Prague, Czech Republic 2003"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0559|cit559","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.1016\/S0924-977X(03)92114-6","article-title":"Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study","volume":"13","author":"Sacchetti","year":"2003","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0560|cit560","first-page":"188","article-title":"Doses of olanzapine, risperidone, and haloperidol in clinical practice: results of a prospective pharmaco-epidemiological study (efeso)","volume":"1","author":"Sacristan","year":"2000","journal-title":"Schizophrenia Research (Abstracts of the 10th Biennial Winter Workshop on Schizophrenia; 2000 Feb 5-11; Davos, Switzerland)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0561|cit561","first-page":"152","article-title":"Olanzapine vs placebo in the treatment of acute mania","volume":"1,2","author":"Sanger T","year":"1998","journal-title":"Schizophrenia Research (9th Biennial Winter Workshop on Schizophrenia, 1998 Feb 7-13, Davos, Switzerland)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0562|cit562","doi-asserted-by":"crossref","unstructured":"Sanger T Tohen M Tollefson GD Jacobs T Olanzapine versus placebo in rapid-cycling bipolar disorder Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum. Glasgow, Scotland, UK; July 12-16, 1998 1998","DOI":"10.1016\/S0924-977X(98)80381-7"},{"issue":"1-2","key":"10.1002\/14651858.CD013425.pub2-BIB0563|cit563","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0165-0327(02)00334-8","article-title":"Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling","volume":"73","author":"Sanger","year":"2003","journal-title":"Journal of Affective Disorders"},{"issue":"1,2","key":"10.1002\/14651858.CD013425.pub2-BIB0564|cit564","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0920-9964(97)88824-X","article-title":"A placebo-controlled trial of olanzapine in psychotic or non-psychotic acute mania","volume":"29","author":"Toben","year":"1998","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0565|cit565","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0920-9964(00)90771-0","article-title":"Olanzapine: acute and long term efficacy in bipolar I patients","volume":"41","author":"Tohen","year":"2000","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0566|cit566","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania","volume":"156","author":"Tohen","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0567|cit567","doi-asserted-by":"crossref","unstructured":"Tohen M Sanger T Tollefson GD McElroy SL Greaney MG Toma V Experience using olanzapine in the treatment of acute bipolar mania 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998 1998","DOI":"10.1016\/S0924-977X(98)80240-X"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0568|cit568","doi-asserted-by":"crossref","unstructured":"Tohen M Sanger T Tollefson GD McElroy SL Greaney MG Toma V Experience using olanzapine in the treatment of acute bipolar mania Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum. Glasgow, Scotland, UK; July 12-16, 1998 1998","DOI":"10.1016\/S0924-977X(98)80240-X"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0569|cit569","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/01.nmd.0000165089.14736.bf","article-title":"Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol","volume":"193","author":"Sayers","year":"2005","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0570|cit570","unstructured":"Sharma M Efficacy and safety of olanzapine versus haloperidol in schizophrenic patients in India http:\/\/www.kgmcindia.edu\/departments\/psychiatry\/psychiatry_fac_res.htm 2003 22417839"},{"issue":"11","key":"10.1002\/14651858.CD013425.pub2-BIB0571|cit571","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1176\/ajp.154.11.1626","article-title":"High dose olanzapine for treatment-refractory schizophrenia","volume":"154","author":"Sheitman","year":"1997","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0572|cit572","unstructured":"Sheitman B Olanzapine versus risperidone for people with schizophrenia hospitalized after a relapse Stanley Foundation Research Awards - 2000 Research Award Recipients (http:\/\/www.stanleyresearch.org\/)"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0573|cit573","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.npp.1300327","article-title":"A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial","volume":"29","author":"Sikich","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0574|cit574","unstructured":"Sikich L Williamson K Malekpour A Bashford RA Hooper S Sheitman B Interim results of a randomized controlled trial of haloperidol, risperidone, and olanzapine in psychotic youth 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco, Mexico 1999"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0575|cit575","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/01.jcp.0000096252.95165.a1","article-title":"The effect of antipsychotics on plasma lipids","volume":"23","author":"Sramek","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0576|cit576","unstructured":"Smelson DA Ziedonis DM Williams JA Losonczy MF Williams J Kaune M A double-blind trial of olanzapine reduces cue-elicited cocaine craving and relapses 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA 2003"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0577|cit577","unstructured":"Smith RC Nigam S Stern A Infante M Mehta R Olanzapine in chronic nonresponding schizophrenia: effects on psychopathology and neurocognitive function 21st Congress of Collegium Internationale Neuro-psychopharmacologicum, Glasgow, Scotland, UK 1998"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0578|cit578","article-title":"Response of chronic nonresponding schizophrenic patients to olanzapine: clinical and neurocognitive effects","volume":"unknown","author":"Smith","year":"2001","journal-title":"Department Psychiatry, NYU Medical School & Manhattan Psychiatric Center"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0579|cit579","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1017\/S146114570100253X","article-title":"The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia","volume":"4","author":"Smith","year":"2001","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0580|cit580","unstructured":"Smith RC Khandat A Infante M Singh A Olanzapine affects neurocognitive function in medication-refractory schizophrenia 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA 2002"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0581|cit581","unstructured":"Smith RC Khandat A Infante M Singh A Olanzapine affects neurocognitive function in medication-refractory schizophrenia Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA Marathon Multimedia 2001 21093232"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0582|cit582","unstructured":"Soutullo CA Sorter MT Foster KD McElroy SL Keck PE Olanzapine in the treatment of adolescent acute mania: preliminary report of seven cases 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998 1998"},{"issue":"16","key":"10.1002\/14651858.CD013425.pub2-BIB0583|cit583","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1001\/jama.283.16.2091","article-title":"Delay in treating schizophrenia may narrow therapeutic window of opportunity","volume":"283","author":"Stephenson","year":"2000","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0584|cit584","doi-asserted-by":"publisher","first-page":"208\u201317","DOI":"10.1093\/schbul\/sbac131","article-title":"Longitudinal network analysis reveals interactive change of schizophrenia symptoms during acute antipsychotic treatment","volume":"49","author":"Sun","year":"2022","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0585|cit585","doi-asserted-by":"crossref","unstructured":"Szafranski T Jarema M Olajossy M Chrzanowski W Araszkiewicz A Landowski J Subjective experiences of schizophrenic patients on atypical antipsychotic olanzapine and typical antipsychotic perphenazine Journal of the European College of Neuropsychopharmacology 1999 S273 21040726","DOI":"10.1016\/S0924-977X(99)80301-0"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0586|cit586","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/10543409608835128","article-title":"Using the proportional odds model to assess the relationship between a multi-item and a global item efficacy scale in a psychiatric clinical trial","volume":"6","author":"Tamura","year":"1996","journal-title":"Journal of Biopharmacological Statistics"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0587|cit587","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0920-9964(03)80201-3","article-title":"Olanzapine causes greater increases in serum lipids than risperidone","volume":"60","author":"Tang","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0588|cit588","first-page":"390","article-title":"A controlled study of olanzapine in treating positive symptoms of schizophrenia","volume":"12","author":"Tang","year":"2004","journal-title":"Heath Psychology Journal"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0589|cit589","first-page":"193","article-title":"Is olanzapine a mood stabilizer?","volume":"41","author":"Tohen","year":"2000","journal-title":"Schizophrenia Research"},{"issue":"9","key":"10.1002\/14651858.CD013425.pub2-BIB0590|cit590","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archpsyc.57.9.841","article-title":"Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study","volume":"57","author":"Tohen","year":"2000","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0591|cit591","unstructured":"Tran PV Tohen M Mazzoti G Silva C Ospina J Gattaz WF Switching psychotic patients with symptomatic extrapyramidal symptoms from haloperidol to olanzapine: results of a multi-center, collaborative trial in Latin America 151st Annual Meeting of American Psychiatric Association. Toronto, ON, Canada; May 30-June 4, 1998 1998"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0592|cit592","unstructured":"Trandafir AI Berk M Brook S Olanzapine versus haloperidol in cannabis induced psychosis: a randomised double-blind trial Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum. Glasgow, Scotland, UK; July 12-16, 1998 1998"},{"issue":"12","key":"10.1002\/14651858.CD013425.pub2-BIB0593|cit593","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.4088\/JCP.v63n1214c","article-title":"Olanzapine treatment for patients with schizophrenia and cocaine abuse","volume":"63","author":"Tsuang","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0594|cit594","first-page":"182","article-title":"Ziprasidone clinical trials conducted in Croatia","volume":"3 Suppl 1","author":"Uzun","year":"2002","journal-title":"Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0595|cit595","unstructured":"Uzun S Kozumplik O Mimica N Folnegovi\u0107-\u0160malc V Treatment with six different antipsychotics: evaluation by scale for the assessment of negative symptoms (SANS) Schizophrenia Research (Abstracts of the in XIIIth Biennial Winter Workshop on Schizophrenia) 2006"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0596|cit596","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.pnpbp.2007.09.007","article-title":"Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation","volume":"32","author":"Villari","year":"2008","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0597|cit597","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1176\/appi.ajp.159.6.1018","article-title":"Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder","volume":"159","author":"Bilder","year":"2002","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0598|cit598","first-page":"195","article-title":"Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder","volume":"3 Suppl 1","author":"Bilder","year":"2002","journal-title":"Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0599|cit599","first-page":"256","article-title":"Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder","volume":"3","author":"Bilder","year":"2001","journal-title":"European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13-17; Istanbul, Turkey)"},{"issue":"11","key":"10.1002\/14651858.CD013425.pub2-BIB0600|cit600","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1176\/appi.ps.52.11.1510","article-title":"Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia","volume":"52","author":"Citrome","year":"2001","journal-title":"Psychiatric Services"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0601|cit601","unstructured":"Citrome LL Volavka J Czobor P Nolan K Lieberman JA Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA 2003"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0602|cit602","unstructured":"Citrome LL Volavka J Czobor P Sheitman BB McEvoy JP Atypical antipsychotics and hostility in schizophrenia: a double-blind study 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA 2002"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0603|cit603","unstructured":"Citrome LL Volavka J Czobor P Sheitman BB McEvoy JP Atypical antipsychotics and hostility in schizophrenia: a double-blind study Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA Marathon Multimedia 2001 21093232"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0604|cit604","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00004714-200206000-00003","article-title":"Antipsychotic-induced weight gain and therapeutic response: a differential association.","volume":"22","author":"Czobor","year":"2002","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0605|cit605","unstructured":"Czobor P Volavka J Citrome LL Sheitman BB McEvoy JP Changes in glucose and cholesterol in schizophrenia treated with atypicals 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA 2002"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0606|cit606","first-page":"S169","article-title":"Changes in glucose and cholesterol levels in schizophrenia patients treated with typical and atypical antipsychotics","volume":"5","author":"Czobor","year":"2002","journal-title":"International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the CollegiumInternationale Neuro-Psychopharmacologicum"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0607|cit607","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0608|cit608","first-page":"1","article-title":"Effects of atypicals on the syndromal profile in treatment-resistant schizophrenia","volume":"unknown","author":"Lindenmayer","year":"2003","journal-title":"156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22, San Francisco, USA"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0609|cit609","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4088\/JCP.v65n0416","article-title":"Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia","volume":"65","author":"Lindenmayer","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0610|cit610","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00004714-200106000-00022","article-title":"Hyperglycemia in patients with schizophrenia who are treated with olanzapine","volume":"21","author":"Lindenmayer","year":"2001","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0611|cit611","unstructured":"Lindenmayer JP Volavka J Lieberman JA Citrome LL Sheitman B McEnvoy JP Do typicals chake the syndromal profile in treatment resistant schizophrenia? 155th Annual Meeting of the American Psychiatric Association, May 18-23, Philadelphia, USA 2002"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0612|cit612","first-page":"284S","article-title":"Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia.","volume":"Suppl 2","author":"Mohr","year":"2000","journal-title":"European Psychiatry (Abstracts of 10th Congress of the Association of European Psychiatrists (AEP); 2000 Oct 28 - Nov 1; Prague, Czech Republic )"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0613|cit613","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jpsychires.2004.04.010","article-title":"Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder","volume":"39","author":"Nolan","year":"2005","journal-title":"Journal of Psychiatric Research"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0614|cit614","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","article-title":"Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"65","author":"Volavka","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0615|cit615","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","article-title":"Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"65","author":"Volavka","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0616|cit616","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01.jcp.0000117424.05703.29","article-title":"Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"24","author":"Volavka","year":"2004","journal-title":"Journal of clinical psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0617|cit617","unstructured":"Volavka J Czobor P Sheitman B Citrome L McEvoy J Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico 2000"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0618|cit618","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.159.2.255","article-title":"Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder","volume":"159","author":"Volavka","year":"2002","journal-title":"American Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD013425.pub2-BIB0619|cit619","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0920-9964(01)00309-7","article-title":"Switching from conventional to novel antipsychotic drugs: Results of a prospective naturalistic study","volume":"57","author":"Voruganti","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"12","key":"10.1002\/14651858.CD013425.pub2-BIB0620|cit620","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jamapsychiatry.2018.3039","article-title":"Effect of damaging rare mutations in synapse-related gene sets on response to short-term antipsychotic medication in Chinese patients with schizophrenia: a randomized clinical trial","volume":"75","author":"Wang","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0621|cit621","unstructured":"McGlashan TH Miller TJ Zipursky RB Woods SW Perkins DO Hawkins KA Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA 2003"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0622|cit622","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0920-9964(02)00439-5","article-title":"The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design","volume":"61","author":"McGlashan","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0623|cit623","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0920-9964(03)80497-8","article-title":"Olanzapine versus placebo treatment of the schizophrenia prodrome: One year results","volume":"60","author":"McGlashan","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0624|cit624","unstructured":"McGlashan TH Zipursky RB Perkins DO Addington JM Woods SW Lindborg S Olanzapine versus pbo for the schizophrenic prodrome: one-year results 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA 2003"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0625|cit625","unstructured":"McGlashan TH Zipursky RB Perkins DO Addington JM Woods SW Lindborg S Olanzapine versus pbo for the schizophrenic prodrome: one-year results 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, USA 2003"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0626|cit626","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0920-9964(02)00440-1","article-title":"The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the \"prodromal\" sample","volume":"61","author":"Miller","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0627|cit627","unstructured":"Woods S Zipursky R Perkins D Addington J Marquez E Breier A Olanzapine versus placebo for prodromal symptoms 3rd International Conference on Early Psychosis; 2002 Sep 26-28; Copenhagen, Denmark 2002 43"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0628|cit628","article-title":"Ransomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome","volume":"in press","author":"Woods","year":"2003","journal-title":"Society of Biological Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0629|cit629","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0920-9964(03)80236-0","article-title":"Olanzapine versus placebo for prodromal symptoms","volume":"60","author":"Woods","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0630|cit630","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0006-3223(03)00321-4","article-title":"Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome.[erratum appears in Biol Psychiatry. 2003 Aug 15;54(4):497]","volume":"54","author":"Woods","year":"2003","journal-title":"Biological Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0631|cit631","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0006-3223(03)00321-4","article-title":"Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome.[erratum appears in Biol Psychiatry. 2003 Aug 15;54(4):497]","volume":"54","author":"Woods","year":"2003","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0632|cit632","first-page":"40","article-title":"Sample size planning for prodromal intervention trials","volume":"3 Suppl 1","author":"Woods","year":"2002","journal-title":"Schizophrenia Research (Abstracts of the 11th Biennial Winter Workshop on Schizophrenia)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0633|cit633","first-page":"125","article-title":"Procedural learning over six months double blind treatment with haloperidol, risperidone or olanzapine","volume":"1-2 Suppl","author":"Woodward","year":"2001","journal-title":"Schizophrenia Research (8th International Congress on Schizophrenia Research; 2001 Apr 28 - May 2; British Columbia, Canada)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0634|cit634","doi-asserted-by":"crossref","unstructured":"King KG Wright P Meehan K Birkett M David SR Taylor CC Transition from intramuscular to oral olanzapine XIIth World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan 2002","DOI":"10.1016\/S0924-9338(02)80468-0"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0635|cit635","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/070674370304801102","article-title":"Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment","volume":"48","author":"Wright","year":"2003","journal-title":"Canadian Journal of Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD013425.pub2-BIB0636|cit636","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1177\/070674370304801102","article-title":"Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment","volume":"48","author":"Wright","year":"2003","journal-title":"Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0637|cit637","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/S0149-2918(03)80129-7","article-title":"A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy","volume":"25","author":"Wright","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0638|cit638","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/S0149-2918(03)80129-7","article-title":"A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy","volume":"25","author":"Wright","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0639|cit639","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/cap.1999.9.239","article-title":"Elevated prolactin in pediatric patients on typical and atypical antipsychotics","volume":"9","author":"Wudarsky","year":"1999","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013425.pub2-BIB0640|cit640","first-page":"S135","article-title":"Depressive symptoms under atypical neuroleptic treatment in schizophrenia.","volume":"71","author":"Yagdiran","year":"2000","journal-title":"Der Nervenarzt (Congress of the Deutsche Gesselschaft fur Psychiatrie, Psychotherapie und Nervenheilkunde: \"Psychiatrie im Jahr 2000 - die europaische Perspektive\", 2000 September 20-23, Aachen, Germany)"},{"issue":"7","key":"10.1002\/14651858.CD013425.pub2-BIB0641|cit641","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jval.2021.11.1374","article-title":"Cost-effectiveness of midazolam versus haloperidol versus olanzapine for the management of acute agitation in the accident and emergency department","volume":"25","author":"Yan","year":"2022","journal-title":"Value in Health"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD013425.pub2-BIB0642|cit642","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1016\/j.euroneuro.2020.09.375","article-title":"Reduction of 5HTR2A protein level in peripheral blood lymphocytes during antipsychotic therapy is associated with absence of common side effects","volume":"40","author":"Zabotina","year":"2020","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0643|cit643","unstructured":"Zhang F Tran PV Taylor C Hwu GH Chen YS Chang WH Efficacy and safety study comparing olanzapine versus haloperidol in the treatment of Chinese patients with schizophrenia in Taiwan and Hong Kong World Psychiatric Association. Hamburg, Germany 1999"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0644|cit644","unstructured":"Ziherl S Novak G Kores-Plesnicar B Kosorok M Juch H Dossenbach M Efficacy and safety of olanzapine in the treatment of schizophrenic, schizophreniform and schizoaffective patients in Slovenia ECNP. London, England, UK 1999"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0645|cit645","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3109\/09540261.2010.515205","article-title":"Sex differences in schizophrenia","volume":"22","author":"Abel","year":"2010","journal-title":"International Review of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0646|cit646","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1192\/bjp.bp.106.029983","article-title":"The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries","volume":"189","author":"Adams","year":"2006","journal-title":"British Journal of Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD013425.pub2-BIB0647|cit647","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003082.pub3","article-title":"Haloperidol versus placebo for schizophrenia","author":"Adams","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0648|cit648","first-page":"39\u201344","article-title":"Assessing depression in schizophrenia: the Calgary Depression Scale","volume":"22","author":"Addington","year":"1993","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0649|cit649","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009693","article-title":"Olanzapine discontinuation for schizophrenia","author":"Alahdab","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0650|cit650","unstructured":"Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewers\u2019 Handbook 4.2.1 [updated December 2003] In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd"},{"issue":"7066","key":"10.1002\/14651858.CD013425.pub2-BIB0651|cit651","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0652|cit652","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-662-01056-3","volume-title":"Das AMDP-System: Manualzur Dokumentation Psychiatricher Befunde","author":"Arbeltsgemelnschaft fur methodik und dokumentation inder psychiatrie (AMDP) [Association for Methodology and Documentation in Psychiatry]","year":"1981"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0653|cit653","doi-asserted-by":"crossref","first-page":"784\u20138","DOI":"10.1001\/archpsyc.1982.04290070020005","article-title":"Negative symptoms in schizophrenia","volume":"39","author":"Andreasen","year":"1982","journal-title":"Archives of General Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD013425.pub2-BIB0654|cit654","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006633.pub2","article-title":"Clozapine versus other atypical antipsychotics for schizophrenia","author":"Asenjo Lobos","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD013425.pub2-BIB0655|cit655","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013219","article-title":"Clozapine versus olanzapine for people with schizophrenia","author":"Asenjo-Lobos","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD013425.pub2-BIB0656|cit656","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013221","article-title":"Clozapine versus risperidone for people with schizophrenia","author":"Asenjo-Lobos","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD013425.pub2-BIB0657|cit657","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006625.pub3","article-title":"Quetiapine versus other atypical antipsychotics for schizophrenia","author":"Asmal","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0658|cit658","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001945","article-title":"Ziprasidone for schizophrenia and severe mental illness","author":"Bagnall","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0659|cit659","first-page":"672\u20136","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"BritishJournal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0660|cit660","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003729.pub2","article-title":"Olanzapine IM or velotab for acutely disturbed\/agitated people with suspected serious mental illnesses","author":"Belgamwar","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0661|cit661","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012073","article-title":"Aripiprazole versus haloperidol for people with schizophrenia and schizophrenia-like psychoses","author":"Bhattacharjee","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD013425.pub2-BIB0662|cit662","doi-asserted-by":"publisher","first-page":"e1003337","DOI":"10.1371\/journal.pmed.1003337","article-title":"The prevalence of mental illness in refugees and asylum seekers: a systematic review and meta-analysis","volume":"17","author":"Blackmore","year":"2020","journal-title":"PLOS Medicine"},{"issue":"7108","key":"10.1002\/14651858.CD013425.pub2-BIB0663|cit663","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0664|cit664","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0665|cit665","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006374.pub2","article-title":"Antipsychotic medication for early episode schizophrenia","author":"Bola","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD013425.pub2-BIB0666|cit666","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012236.pub2","article-title":"Interventions for prodromal stage of psychosis","author":"Bosnjak Kuharic","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0667|cit667","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0920-9964(98)00146-7","article-title":"Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and \u03b11-adrenergic receptors in vitro","volume":"37","author":"Bymaster","year":"1999","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0668|cit668","doi-asserted-by":"crossref","first-page":"388\u201396","DOI":"10.1093\/schbul\/10.3.388","article-title":"The quality of life scale: an instrument for rating the schizophrenic deficit syndrome","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophrenia Bulletin"},{"issue":"10","key":"10.1002\/14651858.CD013425.pub2-BIB0669|cit669","doi-asserted-by":"publisher","first-page":"681\u201390","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0670|cit670","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophrenia Bulletin"},{"issue":"s56","key":"10.1002\/14651858.CD013425.pub2-BIB0671|cit671","doi-asserted-by":"publisher","first-page":"s71","DOI":"10.1192\/bjp.bp.114.153866","article-title":"Estimating the cost of implementing district mental healthcare plans in five low-and middle-income countries: the PRIME study","volume":"208","author":"Chisholm","year":"2016","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0672|cit672","unstructured":"Chouinard G Ross-Chouinard A Annable L Extrapyramidal symptom rating scale Canadian Journal of Neurological Science 1980 7 233"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0673|cit673","volume-title":"COSTART Coding Symbols for Thesaurus of Adverse Reaction Terms","year":"1990"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0674|cit674","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009539","article-title":"Typical antipsychotics for psychosis in adolescents","author":"Datta","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0675|cit675","first-page":"24\u20138","article-title":"Psychometric properties of the Subjective Well-Being Under Neuroleptics Scale (SWN) and the SubjectiveDeficit Syndrome Scale (SDSS)","volume":"162","author":"Haan","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0676|cit676","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0677|cit677","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0678|cit678","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001948.pub2","article-title":"Zotepine for schizophrenia","author":"DeSilva","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0679|cit679","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0680|cit680","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009831.pub2","article-title":"Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders","author":"Dold","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD013425.pub2-BIB0681|cit681","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001951.pub2","article-title":"Haloperidol dose for the acute phase of schizophrenia","author":"Donnelly","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"19","key":"10.1002\/14651858.CD013425.pub2-BIB0682|cit682","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0683|cit683","unstructured":"Haloperidol - usual adult dose for schizophrenia https:\/\/www.drugs.com\/dosage\/haloperidol.html#Usual_Adult_Dose_for_Schizophrenia"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0684|cit684","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001359.pub2","article-title":"Olanzapine for schizophrenia","author":"Duggan","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7109","key":"10.1002\/14651858.CD013425.pub2-BIB0685|cit685","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0686|cit686","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004578.pub3","article-title":"Aripiprazole for schizophrenia","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0687|cit687","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD013425.pub2-BIB0688|cit688","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.cpr.2013.07.001","article-title":"Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions","volume":"33","author":"Elis","year":"2013","journal-title":"Clinical Psychology Review"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0689|cit689","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000059.pub2","article-title":"Clozapine versus typical neuroleptic medication for schizophrenia","author":"Essali","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0690|cit690","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011408.pub2","article-title":"Haloperidol discontinuation for people with schizophrenia","author":"Essali","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0691|cit691","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001944.pub2","article-title":"Thioridazine for schizophrenia","author":"Fenton","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0692|cit692","first-page":"222","article-title":"The Hillside Akathisia Scale: a new rating instrument for neuroleptic induced akathisia.","volume":"25","author":"Fleischhacker","year":"1989","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0693|cit693","first-page":"11","article-title":"Compliance with antipsychotic drug treatment: influence of side effects","volume":"382","author":"Fleischhacker","year":"1994","journal-title":"Acta Psychiatrica Scandinavica. Supplementum"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0694|cit694","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-Mental State:a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatric Research"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0695|cit695","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"9","key":"10.1002\/14651858.CD013425.pub2-BIB0696|cit696","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002306.pub2","article-title":"Risperidone versus other atypical antipsychotic medication for schizophrenia","author":"Gilbody","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0697|cit697","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0698|cit698","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","article-title":"Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria","volume":"56","author":"Green","year":"2004","journal-title":"Biological Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD013425.pub2-BIB0699|cit699","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0700|cit700","article-title":"Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology","volume":"unknown","author":"Guy","year":"1976","journal-title":"National Institute of Mental Health"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0701|cit701","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004410","article-title":"New generation antipsychotics for first episode schizophrenia","author":"Hamann","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0702|cit702","doi-asserted-by":"crossref","first-page":"56\u201362","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology. Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0703|cit703","first-page":"76\u20139","article-title":"Diagnosis and Rating of Anxiety","volume":"S3","author":"Hamilton","year":"1969","journal-title":"BritishJournal of Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD013425.pub2-BIB0704|cit704","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012833","article-title":"Haloperidol (route of administration) for people with schizophrenia","author":"Hanafi","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD013425.pub2-BIB0705|cit705","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011885","article-title":"Switching antipsychotic for non response in schizophrenia","author":"Helfer","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0706|cit706","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007947","article-title":"Olanzapine depot for schizophrenia","author":"Herath Mudiyanselage","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0707|cit707","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007947","article-title":"Olanzapine depot for schizophrenia","author":"Herath Mudiyanselage","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7414","key":"10.1002\/14651858.CD013425.pub2-BIB0708|cit708","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0709|cit709","doi-asserted-by":"crossref","unstructured":"Higgins JP Green S Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org 10.1002\/9780470712184","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0710|cit710","unstructured":"Higgins JP Green S Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0711|cit711","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0712|cit712","doi-asserted-by":"crossref","first-page":"177\u201383","DOI":"10.1017\/S0033291700050182","article-title":"A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity","volume":"13","author":"Hogan","year":"1983","journal-title":"Psychological Medicine"},{"issue":"11","key":"10.1002\/14651858.CD013425.pub2-BIB0713|cit713","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005146.pub3","article-title":"Haloperidol plus promethazine for psychosis-induced aggression","author":"Huf","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10202","key":"10.1002\/14651858.CD013425.pub2-BIB0714|cit714","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0715|cit715","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000440","article-title":"Risperidone versus typical antipsychotic medication for schizophrenia","author":"Hunter","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9007","key":"10.1002\/14651858.CD013425.pub2-BIB0716|cit716","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0140-6736(96)90153-1","article-title":"Redundancy, disaggregation, and the integrity of medical research","volume":"347","author":"Huston","year":"1996","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0717|cit717","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0718|cit718","volume-title":"Evaluation and Diagnosis of Drug-Enduced Extrapyramidal Symptoms: Commentary on the DIEPSS and guide to its usage","author":"Inada","year":"1996"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0719|cit719","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/schbul\/sbs130","article-title":"A systematic review and meta-analysis of recovery in schizophrenia","volume":"39","author":"Jaaskelainen","year":"2013","journal-title":"Schizophrenia bulletin"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0720|cit720","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005237.pub2","article-title":"Risperidone versus olanzapine for schizophrenia","author":"Jayaram","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9690","key":"10.1002\/14651858.CD013425.pub2-BIB0721|cit721","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S0140-6736(09)61253-8","article-title":"Severe mental disorders in complex emergencies","volume":"374","author":"Jones","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0722|cit722","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0723|cit723","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004027.pub2","article-title":"Antipsychotic medication for childhood-onset schizophrenia","author":"Kennedy","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0724|cit724","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006569.pub5","article-title":"Aripiprazole versus other atypical antipsychotics for schizophrenia","author":"Khanna","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0725|cit725","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006752.pub2","article-title":"Sertindole versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0726|cit726","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006627.pub2","article-title":"Ziprasidone versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0727|cit727","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006654.pub2","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0728|cit728","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006624.pub2","article-title":"Amisulpride versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0729|cit729","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006626.pub2","article-title":"Risperidone versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0730|cit730","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2165\/00003088-199937060-00001","article-title":"Pharmacokinetics of haloperidol","volume":"37","author":"Kudo","year":"1999","journal-title":"Clinical pharmacokinetics"},{"issue":"10","key":"10.1002\/14651858.CD013425.pub2-BIB0731|cit731","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009582.pub2","article-title":"Atypical antipsychotics for psychosis in adolescents","author":"Kumar","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0732|cit732","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013266","article-title":"Olanzapine dose for people with schizophrenia","author":"Latifeh","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0733|cit733","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/9781119536604.ch4","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Lefebvre","year":"2019"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0734|cit734","doi-asserted-by":"crossref","first-page":"369\u201373","DOI":"10.1001\/archpsyc.1983.01790040023003","article-title":"The well being of chronic mental patients:assessing their quality of life","volume":"40","author":"Lehman","year":"1983","journal-title":"Archives of General Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD013425.pub2-BIB0735|cit735","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0736|cit736","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophrenia Research"},{"issue":"2-3","key":"10.1002\/14651858.CD013425.pub2-BIB0737|cit737","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0738|cit738","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD013425.pub2-BIB0739|cit739","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0740|cit740","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008016.pub2","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","author":"Leucht","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0741|cit741","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004278.pub2","article-title":"Haloperidol versus chlorpromazine for schizophrenia","author":"Leucht","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0742|cit742","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia","volume":"177","author":"Leucht","year":"2020","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0743|cit743","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001715.pub2","article-title":"Sertindole for schizophrenia","author":"Lewis","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0744|cit744","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013310","article-title":"Olanzapine versus placebo for people with schizophrenia","author":"Li","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"334","key":"10.1002\/14651858.CD013425.pub2-BIB0745|cit745","first-page":"100","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"76","author":"Lingjaerde","year":"1987","journal-title":"ActaPsychiatrica Scandinavica Supplementum"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0746|cit746","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.brainresbull.2009.01.005","article-title":"The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice","volume":"79","author":"Lopez-Munoz","year":"2009","journal-title":"Brain research bulletin"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0747|cit747","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S2215-0366(18)30060-9","article-title":"Social determinants of mental disorders and the Sustainable Development Goals: a systematic review of reviews","volume":"5","author":"Lund","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0748|cit748","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0749|cit749","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004718.pub3","article-title":"Early intervention for psychosis","author":"Marshall","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0750|cit750","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1741-7015-2-13","article-title":"A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology","volume":"2","author":"McGrath","year":"2004","journal-title":"BMC Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0751|cit751","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiologic Reviews"},{"issue":"7400","key":"10.1002\/14651858.CD013425.pub2-BIB0752|cit752","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/bmj.326.7400.1171","article-title":"Evidence b (i) ased medicine\u2014selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications","volume":"326","author":"Melander","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0753|cit753","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.socscimed.2009.09.029","article-title":"War exposure, daily stressors, and mental health in conflict and post-conflict settings: bridging the divide between trauma-focused and psychosocial frameworks","volume":"70","author":"Miller","year":"2010","journal-title":"Social Science & Medicine"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0754|cit754","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"British Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0755|cit755","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.cct.2004.09.002","article-title":"An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia","volume":"25","author":"Montgomery","year":"2004","journal-title":"Controlled Clinical Trials"},{"issue":"7","key":"10.1002\/14651858.CD013425.pub2-BIB0756|cit756","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009377.pub3","article-title":"Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)","author":"Ostinelli","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0757|cit757","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12916-017-0960-z","article-title":"Mapping the evidence on pharmacological interventions for non-affective psychosis in humanitarian non-specialised settings: a UNHCR clinical guidance","volume":"15","author":"Ostuzzi","year":"2017","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0758|cit758","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1017\/S2045796022000166","article-title":"Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries","volume":"31","author":"Ostuzzi","year":"2022","journal-title":"Epidemiology and Psychiatric Sciences"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0759|cit759","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/wps.20972","article-title":"Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants","volume":"21","author":"Ostuzzi","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0760|cit760","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0761|cit761","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00434408","article-title":"The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review","volume":"71","author":"Parrott","year":"1980","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0762|cit762","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/002076409904500102","article-title":"Application and results of the Manchester Short Assessment of Quality of Life (MANSA)","volume":"45","author":"Priebe","year":"1999","journal-title":"International Journal of Social Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0763|cit763","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001361","article-title":"Depot haloperidol decanoate for schizophrenia","author":"Quraishi","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD013425.pub2-BIB0764|cit764","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012728","article-title":"Haloperidol versus risperidone for schizophrenia","author":"Ray","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0765|cit765","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0766|cit766","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment\u2013pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0767|cit767","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/ebmental-2020-300151","article-title":"Classification of psychotherapy interventions for people with schizophrenia: development of the Nottingham Classification of Psychotherapies","volume":"24","author":"Roberts","year":"2021","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0768|cit768","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","article-title":"Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis","volume":"399","author":"Schneider-Thoma","year":"2022","journal-title":"Lancet"},{"issue":"16","key":"10.1002\/14651858.CD013425.pub2-BIB0769|cit769","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3238\/arztebl.2010.0279","article-title":"The financing of drug trials by pharmaceutical companies and its consequences: part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials","volume":"107","author":"Schott","year":"2010","journal-title":"Deutsches \u00c4rzteblatt International"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0770|cit770","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0006-8993(93)91535-Z","article-title":"Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography","volume":"631","author":"Schotte","year":"1993","journal-title":"Brain Research"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0771|cit771","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"Jama"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0772|cit772","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In Higgins JP, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0773|cit773","first-page":"440\u20138","article-title":"Haloperidol: a quarter century ofexperience","volume":"44","author":"Settle","year":"1983","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0774|cit774","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/10673220600748486","article-title":"Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome","volume":"14","author":"Shirzadi","year":"2006","journal-title":"Harvard Review of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD013425.pub2-BIB0775|cit775","doi-asserted-by":"publisher","first-page":"209","DOI":"10.15171\/bi.2017.25","article-title":"Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis","volume":"7","author":"Shokraneh","year":"2017","journal-title":"BioImpacts"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0776|cit776","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13643-019-1035-3","article-title":"Study-based registers reduce waste in systematic reviewing: discussion and case report","volume":"8","author":"Shokraneh","year":"2019","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0777|cit777","doi-asserted-by":"publisher","first-page":"sgaa061","DOI":"10.1093\/schizbullopen\/sgaa061","article-title":"Cochrane Schizophrenia Group\u2019s study-based register of randomized controlled trials: development and content analysis","volume":"1","author":"Shokraneh","year":"2020","journal-title":"Schizophrenia Bulletin Open"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0778|cit778","doi-asserted-by":"publisher","DOI":"10.1111\/hir.12366","article-title":"Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: a study-based analysis","volume":"In Press","author":"Shokraneh","year":"2021","journal-title":"Health Information and Libraries Journal"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0779|cit779","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001357","article-title":"Amisulpride for schizophrenia","author":"Silveira da Mota Neto","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0780|cit780","first-page":"11\u20139","article-title":"A rating scale for extrapyramidal side-effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0781|cit781","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000967.pub2","article-title":"Quetiapine for schizophrenia","author":"Srisurapanont","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0782|cit782","unstructured":"Sterne JA Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention . Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"10","key":"10.1002\/14651858.CD013425.pub2-BIB0783|cit783","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006628.pub3","article-title":"Zotepine versus other atypical antipsychotics for schizophrenia","author":"Subramanian","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0784|cit784","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007815.pub2","article-title":"Quetiapine versus typical antipsychotic medications for schizophrenia","author":"Suttajit","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD013425.pub2-BIB0785|cit785","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009268.pub2","article-title":"Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia","author":"Tardy","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0786|cit786","volume-title":"The Maudsley Prescribing Guidelines in Psychiatry","author":"Taylor","year":"2018"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0787|cit787","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12874-018-0554-2","article-title":"Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Medical Research Methodology"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0788|cit788","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001189","article-title":"Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database","volume":"9","author":"Turner","year":"2012","journal-title":"PLOS Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013425.pub2-BIB0789|cit789","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000966","article-title":"Newer atypical antipsychotic medication versus clozapine for schizophrenia","author":"Tuunainen","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD013425.pub2-BIB0790|cit790","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0791|cit791","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Sherbourne","year":"1992","journal-title":"Medical Care"},{"issue":"12","key":"10.1002\/14651858.CD013425.pub2-BIB0792|cit792","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s40263-013-0115-5","article-title":"Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor","volume":"27","author":"Weston-Green","year":"2013","journal-title":"CNS drugs"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0793|cit793","unstructured":"World Health Organization WHOQOL-BREF: introduction, administration, scoring and generic version of the assessment: field trial version, December 1996 (No. WHOQOL-BREF) Available at https:\/\/apps.who.int\/iris\/handle\/10665\/63529 1996"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0794|cit794","unstructured":"World Health Organization Mental health atlas 2020 Available at https:\/\/apps.who.int\/iris\/handle\/10665\/345946"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0795|cit795","unstructured":"World Health Organization World mental health report: transforming mental health for all Available at https:\/\/www.who.int\/publications\/i\/item\/9789240049338"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0796|cit796","unstructured":"World Health Organization WHO 24th Expert Committee on Selection and Use of Essential Medicines Available at www.who.int\/groups\/expert-committee-on-selection-and-use-of-essential-medicines\/24th-eml-expert-committee"},{"key":"10.1002\/14651858.CD013425.pub2-BIB0797|cit797","unstructured":"World Health Organization WHO model list of essential medicines Available at https:\/\/apps.who.int\/iris\/handle\/10665\/345533 2023 23rd list 66"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0798|cit798","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004965","article-title":"Interventions for psychosis in adolescents","author":"Wright","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013425.pub2-BIB0799|cit799","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1745-6215-10-46","article-title":"Randomized trials published in some Chinese journals: how many are randomized?","volume":"10","author":"Wu","year":"2009","journal-title":"Trials"},{"issue":"7","key":"10.1002\/14651858.CD013425.pub2-BIB0800|cit800","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"6","key":"10.1002\/14651858.CD013425.pub2-BIB0801|cit801","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1192\/bjp.179.6.503","article-title":"Extrastriatal and striatal D 2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia","volume":"179","author":"Xiberas","year":"2001","journal-title":"British Journal of Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD013425.pub2-BIB0802|cit802","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012811","article-title":"Aripiprazole versus ziprasidone for schizophrenia","author":"Yang","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD013425.pub2-BIB0803|cit803","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011655.pub2","article-title":"Chlorpromazine versus metiapine for schizophrenia","author":"Zare","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD013425.pub2-BIB0804|cit804","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013425","article-title":"Haloperidol versus olanzapine for people with schizophrenia","author":"Ibragimov","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:27:17Z","timestamp":1761762437000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013425.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Z_INACTIVE_Schizophrenia Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":804,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013425.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]}}}